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1 Introduction 
1.1 Types of stroke, incidence rates and pathology 
 
Stroke is classified by the World Health Organisation (WHO) as a pathological acute brain 
disease of cerebrovascular origin and can lead to long-lasting neurological impairment or 
even death. Deprivation or interruption of oxygen and nutrients by undersupply of blood 
through intracranial vessels can cause heavily and irreparably damage in distinct brain 
regions, which results in functional deficits such as aphasia, apraxia, attenuation in 
concentration and memory, hemiparesis or neglect. (Hartmann, A., 2001). Stroke is the third 
leading cause of mortality and first listed for severe disability and intensive aftercare in the 
United States and Federal Republic of Germany (Hinkle, J.L., 2007, Thom, T., 2006, 
Eschenfelder, C.C., 2006, Statistisches Jahrbuch: Statistisches Bundesamt, Wiesbaden 2003).  
 
1.1.1 Types of stroke of arterial origin 
Evaluation of annual stroke registration (Eschenweiler, C.C., 2006, ESPro - The Erlangen 
Stroke Project) reveals an incidence of approximately 79% for ischemic stroke and 18% for 
cerebral hemorrhages of arterial origin. About 3% had stroke of unspecified type 
(Kolominsky-Rabas, PL, 1998, 2002). Within these two different types of arterial stroke, 
detailed classifications are defined to describe the course of pathology. 
 
1.1.1.1 Ischemic stroke 
The clinical course of ischemic stroke is delicately subdivided into different episodes. 
A transient ischemic attack (TIA) shows described neurological symptoms after onset of 
stroke, which declines and vanish within 24 h or less. Sustained neurological disability more 
than 24 h, but less than a week with minor to full functional recovery is defined as reversible 
ischemic neurological deficit or “RIND”.  
Moreover, neurological dysfunction after onset of stroke can maintain for hours until days 
without remission of symptoms. This progressive form of stroke is severe due to long-lasting 
moto- and senso-functional disability, but can also induce speech disorder.    
A major stroke or complete stroke results in clinical deficits with partial or no remission of 
the neurological symptoms and lead to irreparable moto-function. Thus, it is diagnostically 
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awkward to differentiate with these terms of definition between RIND, progressive or 
progredient and major stroke (Caplan, L.R., 1983).  
Occlusions of large intracranial arteries account for 79% of ischemic stroke cases. Insults of 
the A. cerebri media or middle cerebral artery (MCA) occur 50-60%, whereas the A. carotis 
interna is affected in 15-25% (Xavier, A.R., 2003).  
 
1.1.1.2 Intracerebral haemorrhages 
Intracerebral haemorrhages are spontaneous bleedings into the brain parenchyma. This type of 
bleeding can be subclasified into supratentorial or infratentorial bleedings depending on their 
anatomical location. Supratentorial bleeding is usually localized within the basal ganglia 
(Solomon, D.H., 1994), whereas infratentorial haematoma is constricted to Pons and 
Cerebellum (Eschenfelder, C.C., 2006). In most cases, hypertonia is responsible for 
spontaneous supratentorial bleeding, which affects predominantly the basal ganglia 
penetrating branches with percentage rates of 40% to 60% of all spontaneous intracerebal 
bleedings (Brott, T., 1986, Fisher, C.M., 2003). Furthermore, vascular abnormalities such as 
aneurysm are responsible for 6% of all intracerebal hemorrhages (Benoit, B.G., 1982). 
Aneurysms are blood-filled saccate or berry-like bulges of the arterial vascular wall, which 
extent the vessel diameter permanently, thus risk for rupturing of blood vessel increases with 
the rate of dilatation. Ehlers-Danlos-Syndrom and Marfan-Syndrom are innate diseases, 
which are also called “connective tissue weaknesses”, and frequently result in aneurysm 
formation (van den Berg, J.S.P., 1996). Moreover, environmental risk factors such as smoking 
or fatty food can abet vascular wall diseases such as artheriosclerosis (Nagai, Y., 2001). 
With respect to latest aetilogical studies, cerebral amyloid angiopathy (CAA) is the second 
most common underlying mechanism of intracerebral haemorrhages with 7-14% in the elderly 
(Vinters, H.V., 1983, Friedmann, E., 1991). The histopathological manifestation of CAA is an 
accumulation of ß-amyloid protein in the arterial vascular wall within the Tunica Adventia, 
which leads to expulsion of the smooth muscle layer in the Tunica Media with demolishing 
consequences to the Lamina externa and interna by loosing their vessel wall integrity and 
flexibility. Due to vascular stenosis, formation of aneurysm and obliteration, affected vessels 
are highly vulnerable for rupturing in the close vicinity of these pathological vascular 
changes. In general, CAA is accompanied with hypertonic microangiopathy (Vinters, H.V., 
1983). Interestingly, ß-amyloid protein in CAA is identical to the plaque forming ß-amyloid 
protein in Alzheimer’s disease (Masters, C.L., 1985).  
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1.1.1.3 Extracerebral hemorrhages 
In the contrary to intracerebral hemorrhages, extracerebral bleeding affects upper vessels on 
the brain surface and especially vessels, which supply the meninges. The A. meningea media 
is at risk during a craniocerebral injury. Arterial blood streams with high pressure between the 
skull and the Dura mater (epidural hemorrhage), occurs fast and results in an elevated ICP. 
Thus, epidural hemorrhages can lead to tremendous life-threatening conditions. Another type 
of extracerebral arterial bleeding without traumatic background is the aneurysmal 
subarachnoid hemorrhage (SAH). Affected vessels are primarily arteries that forme the so 
called “Circulus arteriosus Willisii”. Within this big anastomostic bloodcircuit, intracranial 
aneurysmal structures can be found in 30% of the cases at the A. communicans anterio, 25% 
at the A. communicans posterior, 20% at the A. cerebri media, 7.5% at the A.carotis interna 
and 7% at the basilar tip. 3% are miscellaneous aneurysms, which are located somewhere else 
(Brisman, L.J., 2006). Leading symptoms for SAH are sudden and severe painful headaches, 
so called “thunderclap headache”, reduction or even loose of consciousness, vomiting and 
meningism.  
 
1.1.2 Types of stroke of venous origin 
In contrast to arterial stroke, cerebral venous thrombosis (CVT) affects intracranial veins and 
sinuses. It is a very rare type of cerebrovascular disease with a prevalence of 5 cases among 1 
million and accounts for 0.5 % for all strokes (Bousser, M.-G., 2007). Furthermore, rupturing 
of bridging veins- branches of the upper veins Vv. superiores cerebri, which cross the 
subarachnoid space and penetrate the Arachnoidea mater to end in the venous Sinus sagittalis 
superior- lead to the formation of an artificial blood-filled space between the Dura mater and 
Arachnoidea mater. This so called “subdural bleeding” results in space-occupying 
haematoma, which, depending on size and location, can compress important brain areas and 
elevate ICP (Trepel, M., 2008). In most cases, acute subdural hemorrhage (ASDH) emerges 
after marked external mechanical forces but also minor traumatic brain injuries (TBI) can 
underlie shearing forces between Dura and Arachnoidea mater. In general, ASDH occur in 
younger adults, after a major trauma accompanied with structural brain injury, and is 
clinically evident within 72h after disease onset (Adhiyaman, V., 2002). The neurological 
literature distinguishes acute from chronic subdural haematoma (CSDH). CSDH is a disease 
pattern predominantly found in the elderly after a trivial injury without directly harming the 
brain parenchymal structures. The course of this event is slow and consistent because of the 
                                                                 Introduction                                                                 .                   
  4 
low blood pressure within the bridging veins. As a consequence, affected patients show signs 
of symptoms such as headache or dizziness one week after lesion onset. This is accompanied 
with neurological disturbed functions (Adhiyaman, V., 2002, Miranda, L.B., 2011). The 
incidence is estimated at 7.4/100.000 per year in the age of 70-79 groups (Bernard, K., 2004, 
Miranda, L.B., 2011). Figure 1 lists and categorizes the mentioned types of stroke. 
 
Figure 1: Schematic illustration of different stroke types. Strokes originate from a 
dysfunction of the vascular (arterial or venous) system. Further categorisation differentiates 
between acute and chronic events. CVT: cerebral venous thrombosis, ASDH: acute subdural 
hemorrhage, CSDH: chronic subdural hemorrhage.   
 
1.1.3 Correlation between affected topographical brain regions and neurological 
dysfunction after infarct of the A. cerebri media territory 
 
Occlusion of the A. cerebri media is one of the most frequently pathogenesis with incidences 
of 50-60% for all ischemic strokes (Xavier, A.R., 2003). The A. cerebri media is the biggest 
branch and a direct continuation of the A. carotis interna. It is most likely that aterio-arterial 
emboli originate from the left ventricle of the heart, passe the A. carotis interna and finally 
occlude the A. cerebri media. The vascular territory of the A. cerebri media includes the 
convex cortical hemispheres including the Lobus insularis (see figure 2).  
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Figure 2: Vascular territory of the major intracerebral arteries.  
a) Lateral view of the cerebrum, b) View of a medio-sagital brain section, c) View of a 
horizontal brain section; 1) Vascular territory of the A. cerebri anterior, 2) Vascular territory 
of the A. cerebri media, 3) Vascular territory of the A. cerebri posterior; I) Capsula interna, 
II) Gyrus precentralis, III) Gyrus postcentralis (Image from Trepel, M, 2008). 
 
 
After an occlusion of the MCA, specific neurological dysfunctions manifest as motoric and 
sensoric disabilities. One-third of all infarct affected in the MCA territory are allocated to the 
lower segments of the A. cerebri media, where branching arteries called Aa. lenticulostriatae 
perforate into deeper brain structures and supply functional areas of the basal ganglia. 
Suppression of blood supply within this part of the A. cerebri media is constricted to the 
vascular territory of cortex and basal ganglia, concurrently (Trepel, M., 2008). Affected 
topological brain structures are located in the somatomotorical dorsal cortex of the frontal 
lobe, the Gyrus precentralis, but also the upper part of the back crural sections of the Capsula 
interna. Neurological deficiency comprises brachiofacial hemiparesis with paralyis of the legs 
or even the whole contralateral side.  
I 
II 
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c 
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Stroke-induced lesions compromising the Gyrus postcentralis, an area of the parietal lobe, 
cause dysfunction of somatosensorical qualities of the contralateral side (face, arms and legs). 
The extent of functional disability during MCA infarcts depend on the duration and 
localization of occlusion in the A. cerebri media as well as its aetiology.  
 
1.1.4 Risk factors  
In the last decades, clinical evidence and epidemiological research identify several risk factors 
for possible stroke events. Such factors include hypertonia, diabetes mellitus, different types 
of heart diseases and lifestyle habits, including smoking, overweight, alcohol abusus and 
gender (Bronner, L.L., 1995). One of the main risk factors for stroke, intracerebral 
hemorrhages, SAH as well as TIA is hypertonia. Level of blood pressure and rate of risk are 
linear correlated. It has been demonstrated that systolic blood pressure values between 120 
and 129mmHg elevate the risk to suffer of stroke by 40% compared to participants with 
values bellow 120mmHg (O’Donnell, C.J., 1997). 
 
1.1.4.1 Smoking  
Meta-analysis of 32 different single studies reveals a 50% higher probability to suffer from 
stroke in smokers (Shinton, R., 1989). Among smokers, heavy smokers (~730 packs/year) are 
2-times more affected to sustain stroke compared to moderate smokers (~182 packs/year). 
Remarkably, the Framingham-Study demonstrates a remission of high risk for smokers to the 
level of non-smokers after 5 years of abdication. The risk declines already to the half after 1 
year after cassation of smoking (Wolf, P.A., 1988). Therefore, reducing or stopping of 
smoking attenuates and decrease behaviour-depending risk factors for stroke.  
 
1.1.4.2 Heart diseases 
Heart diseases represent an important risk factor for stroke. Risk for cardiac dysfunction, 
coronar heart diseases, cardiac insufficiency, leftventricular hypertrophy and atrial fibrillation 
elevates in the elderly simultaneously with the risk for stroke. Coronary heart disease and 
ventricular hypertrophy can fortify risk for ischemic insult. Moreover, cardiac insufficiency 
can increase the risk for stroke events by 3-times and arterial fibrillation even by 5-times 
(Wolf, P.A., 1991). Stroke patients with atrial fibrillation have a higher risk to suffer for 
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intracranial vessel occlusion by an embolus originated from the left ventricle 
(Bougousslavsky, J, 1990). 
 
1.1.4.3 Diabetis mellitus 
The metabolic disorder diabetes mellitus is another important risk factor for cerebral stroke. 
In many studies, diabetics have shown high prevalence for cardiovascular heart disease such 
as hypertonia, adiposity and dyslipoproteinaemia. The PROCAM-Study was celarly able to 
demonstrate a direct coherence between diabetes mellitus and stroke. The study involved men 
from 30-64 years of age. Beside a higher incidence of artherosclerosis, reduced fibronolytic 
activity, aggregation of thrombocytes together with high levels of fibrinogen factor 7 and 8 
might play an important role (Berger, K., 1998, Mallinow, M. R., 1997, Manson, J. E., 1991).  
 
1.1.4.4 Overweight 
Another behavioural-dependent risk factor besides smoking is overweight, which, in the first 
place, can be the result of missing sporty activity and unhealthy food uptake. High blood 
pressure, dyslipoproteinaemy, hyperinsulinemia or disturbed glucose metabolism are 
additionally accompanied with overweight as independent risk factors. Studies identified 
overweight as an independent hazard factor for stroke. “Bodymass-Index” or “Waist-to-hip-
Ratio” reveals a direct correlation between abdominal adiposity and stroke risk (Walker, S.P., 
1996, Shinton, R. 1991, 1995). The insensitivity for insulin inhibition on lipophilc reactions 
of intra-abdominal fatty tissue compared to skin fat might be one major reason. Due to the 
increase of intra-abdominal fatty tissue, abnormal levels of fatty acid within the liver can be 
measured. Thus, high concentrations of free available fatty acids results in 
dyslipoproteinemia, high blood pressure etc. which can provoke in final stages atherosclerotic 
plaques within the arterial vessel wall (Bjorntop, P., 1990).   
Extensive clinical data analysis such as the Framingham, Physician Health or the Honolulu 
Heart Study are suggesting physical or regular sport activities as preventing and stroke-risk-
factor reducing parameters. Risk factors decreased about 40-50% in women as well in men, 
respectively (Abbott, R.D., 1994, Lee, I.M., 1999, Wolf, P.A., 1988).  
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1.1.4.5 Gender-specific and age-related differences are risk factors for stroke 
Incidence and outcome of ischemic and traumatic brain injury alters between sexes and with 
ages. Moreover, it is characterized by a significantly different male-to-female ratio being 
higher in male (Herson, P.S., 2009). Epidemiological studies reveal male sex as a risk factor 
for stroke (Giroud, M., 1991, Bogousslavsky, J. 1988, Sacco, R.L., 1998). This gender-
dependent dimorphic disease pattern maintains apparent until ages before menopause (Giroud, 
M. 1991, Appelros, P. 2008, Bushnell, C.D., 2007). Furthermore, stroke risk increases with 
age in both genders, and there are broad evidences that outcome from stroke is worse in 
reproductively senescent women and women within the menopause than in their male 
counterparts (Appelros, P. 2008, Di Carlo, A., 2003). In the elderly, the risk factor profile for 
stroke differs between women and men. For instance, women are more vulnerable to have 
atrial fibrillation and hypertension, whereas men are more likely to suffer from coronary 
artery disease (Holroyd-Leduc, J.M., 2000, Roquer, J., 2003, Kapral, M.K., 2003).   
Recently published studies showed sex-specific responses to acute stroke thrombolysis. 
Women who were treated with tissue plasminogen activator (t-PA) had a better clinical 
outcome after 90 days compared to their placebo-group. On the contrary, outcome of t-PA-
treated men revealed a slightly improvement after lysis compared to men without t-PA 
medication. Interestingly, placebo-treated women displayed a significantly worse outcome 
than placebo-treated men (Kent, D.M., 2005, Hill, M.D., 2006). Additionally, women, who 
received t-PA, showed highly improved outcome already after 24 h compared to men 
(Saposnik, G., 2006). 
 
   
1.1.5 Therapy and prevention 
Hitherto, there is less common acceptable therapy for acute stroke. Specialized “stroke units”, 
which are affiliated to neurological departments, ensure clinical diagnosis for instance by 
magnetic resonance imaging and provide the appropriate therapy including medicamentous 
lysis of blood clots or surgical intervention. Members of stroke units usually include 
neurologists, internists, neuroradiologists, and experienced nursing staff. Directly after 
therapy, rehabilitation programs to set up early recovery procedure for the patient. Therefore, 
special skilled physiotherapists, speech therapists and occupational therapist are locally 
resident.  
The correct interpretation of a computer tomograph (CT) or magnetic resonance scanning to 
exclude hemorrhage is crucial within a time frame from 3-6 h after stroke onset. The 
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immediate thrombolytic recanalisation after diagnostical determination of stroke with 
ischemic origin results in considerable recovery, smaller infarcts and ameliorates the 
functional outcome (Wechsler, L., 2000, Young, A.R., 1997). Until now systemic intra-
venous or catheter-supported local intra-arterial thrombolysis with 0.9 mg recombinant tissue-
plasminogen activator (rtPA)/kg BW is the only medicamentous way of treatment for acute 
ischemic stroke. Treatment should start within 3h after stroke onset after CT imaging 
excluded hemorrhage definitely (Hacke, W., Poeck, K., 2001, The NINDS rt-PA Stroke Study 
Group 1995). After lysis, antihypertensive (Angiotensin Converting Enzyme, ACE) and 
blood-thinning medicaments (acetylsalicylic acid, heparin or phenprocoumon) are subscribed 
as preventive prophylaxis (Hartmann, A, 2001).  
Since several years, research aims to develop treatment strategies, e. g., against oxidative 
stress (ROS, free radicals etc.) or excitatory amino acid such as glutamate (see 1.2.2) to 
prolong neuronal cell survival after ischemia. A lot of promising substances were investigated 
in animal experiments with impressive effects on reducing the lesion volume and neurological 
deficits. Unfortunately, all clinical trials hitherto failed. Some reasons might be the timing of 
application in the animal experimental set up, which were before or during experimentally-
induced stroke. Application after 24h or even 48h of stroke did not depict the clinical 
scenario. Moreover, some substances caused unexpected serious side effects such as 
psychosis, hypotonia and agitation in clinical trials (Wahlgren, N.G., 2004).               
 
 
1.2 Pathobiological mechanism of ischemic progression 
 
Brain tissue requires high level of glucose and oxygen to provide energy-consuming cellular 
mechanisms, which are responsible to maintain the intracellular homoeostasis. Metabolic 
pathways such as glycolysis or the citric acid cycle provide in several biochemical steps the 
energetic equivalent adenosintriphosphat (ATP) from adenosindiphosphat (ADP) by oxidative 
phosphorylation. Within seconds to minutes of inadequate blood supply provoked by 
ischemic events, crucial cascades of biochemical reactions take place to counteract 
deprivation of oxygen and glucose by switching to anaerobic metabolism. Especially in 
neurons, levels of ATP and glucose drop down close to the minimum, whereas in the same 
time lactate level accumulates (Lowry, O.H., 1964). Increase of lactate production and ATP 
consumption concurrently raises intracellular hydrogen ion concentration (H+). Counteractive 
stabilization of homeostatic conditions remain ineffective based on failure of ATP-depending 
membrane anchored H+-K+-pumps, which could transport H+ into the extracellular milieu. In 
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particular, malfunction of the Na-K-ATPase pump leads to imbalance of ionic homeostasis 
within the cell. Rebalancing of ionic distribution along the pre-synaptic membran by ordinary 
non-selective ion- or water channels fail after a certain threshold. In normal circumstances, 
the resting membrane potential at the axon terminal shows intracellular negative polarisation 
compared to the extracellular space.  
Basically, to maintain the status quo the most important ions such as K+, Na+, Ca2+ and Cl- are 
precisely distributed along the membrane. High concentration of potassium is evident within 
the cell, whereas sodium, calcium and chloride can be found in greater amounts 
extracellularily (Alberts, B., 2004). According to the law of diffusion, these ions cross the 
membrane through specific ion channels (e.g. potassium ion channel) to equalize the 
concentration gradient. In the cytosol, anionic proteins are present in high concentration, thus 
different membrane transport systems are required within the membran to counteract the 
osmotic reactions to maintain the electrical gradient. ATP-depending shuttled transporter 
systems (e.g. Na-K-ATPase pump) in the plasma membrane actively pump the surplus of 
sodium and calcium into the extracellular space. In neurons, ischemic conditions cause 
depolarisation in the pre-synaptic terminal mainly due to lactate accumulation and ischemic-
induced failure of ATPase pumps (Siesjö, B., 1988). As a consequence, the depolarization 
opens voltage-depending, calcium-selective ion channels located in the pre-synaptic 
membrane resulting in influx of calcium into the cell. Via calcium-binding mechanism on 
synaptic vesicle containing neurotransmitters, the release of these messengers is triggered into 
the synaptic cleft via exocytosis. Independent of neurotransmitters, the transmission occurs 
rapidly by ligand-receptor interaction on the post-synaptic side (Nicholls, D., 1999). For 
another signal incoming, removal of neurotransmitter in the synaptic cleft and especially on 
the receptor is either catalysed through enzymes (e.g. acetylcholin esterase) or is re-uptaked 
by the pre-synaptic membrane via specific symporters or ATP-consuming transporters. 
Restoration of the synaptic cleft is also enhanced by diffusion processes, which disperse the 
neurotransmitter into the adjacent border. Despite of degradation by enzymes, breakdown of 
ATP-gated reuptake mechanisms caused fatal high accumulation of neurotransmitters, which 
diffuse uncontrolled and react with receptors on other neurons.  
 
1.2.1 Glutamate excitotoxicity  
One of the most important and ubiquitous excitatory amino acid neurotransmitters in the 
central nervous system (CNS) is L-glutamate. Under above mentioned ischemic pathological 
conditions, the accumulation of high concentration of glutamate in the synaptic cleft results in 
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dispersion and causes non desirable continuous activation on neighboured neuronal ionotropic 
and metabotropic glutamate receptors located post-synaptically. Persistent binding on 
ionotrophic receptors such as NMDA (N-methyl D-aspartate), AMPA (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid) or kainate receptors evokes overload influx of calcium 
(Hazell, A.S., 2003, Hollmann, M., 1991). In contrast to AMPA and kainite receptors, which 
are permeable to K+ and Na+ as well as to Ca2+ to a lower level, NMDA receptors are voltage-
dependent and ligand-gated receptors, which are highly permeable to Ca2+. The existing 
concentration gradient causes binding of glutamate to AMPA or kainite receptors and 
provokes high influx of Na+ and in smaller amounts of calcium into the postsynaptic neuron 
and a slowly K+ outflow into the synaptic cleft. Water streams passively intracellularly and 
causes cell swelling. As a result, the membrane depolarizes and leads to an active potential or 
excitatoric post-synaptical potential (EPSP), which opens the glutamate-mediated NMDA 
receptor for calcium (Hossmann, K.-A., 1994a, Turski, L., 1998).  
Metabotropic glutamate receptors (mGluRs) are G-protein coupled receptors that trigger 
upper- and downstream signalling regulation involving membrane- anchored protein kinase C, 
cyclic AMP or phosphoinositide-dependent mechanism (Choi, D., 1988). Activation of 
mGluRs increase intracellular Ca2+ concentration by second-messenger-mediation of inositol 
1,4,5-trisphosphate (IP3), which binds on ligand-gated IP3-receptors on the endoplasmic 
reticulum (ER). Sustained overactivation of mGluRs by glutamate excitotoxicity mediates 
abnormal intracellular calcium release from the ER.  Concomitantly, the decline of calcium in 
the ER evokes ER-stress, manifested by protein misfolding, disturbances in protein synthesis 
and expression of stress proteins. Free cytosolic Ca2+ is a key signalling agent and has 
versatile important regulatory mechanisms e.g. vehicle release via exocytosis, enzymatic 
regulation or controlling of channels to maintain cytosolic homeostasis (Lemasters, L.L. 
2009). Uncontrolled rise of cytosolic Ca2+ upregulates calcium-dependent catabolic enzymes 
and provoke mitochondrial disturbances (Paschen, W.1996). 
 
1.2.2 Calcium-mediated neurotoxicity 
Under normal conditions, the intracellular concentration of Ca2+ ions is tightly controlled by 
highly efficient calcium transport systems to maintain the cellular homeostasis. Within the 
cell, gradients between the cytosol and the cell compartments such as ER or mitochondria are 
also strictly regulated. Following ischemic conditions, these cellular transport systems break 
down leading to high influx of calcium into the cell. The calcium ion activity and the release 
of endogenous calcium by the ER or mitochondrium elevate intracellular calcium levels to a 
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neurotoxic degree. The overload of calcium ions triggers intracellular second messenger 
signalling cascades, which are usually regulated and controlled under physiological 
conditions. Ca2+-binding proteins such as calmodulin, which is a versatile, intracellular Ca2+-
receptor, can interact with Ca2+/calmodulin-depending protein kinases (CaM-Kinases) but 
also the binding of free calcium to membrane-anchored proteinase c (PKC) can activate gene 
as well as protein regulation. The latter comprises regulation of the NF-κB pathway, CREP-
induced signalling directly or indirectly activating proteases, kinases, phospholipases and 
endonucleotidases (Racioppi, L., 2008, Feske, S., 2007, Klein, J., 1997, Du, K., 1998, 
Berridge, M. J., 2003). Calcium-mediated neurotoxicity is a complex event and the impact of 
its fatal outcome is restricted to the degree of ischemia. 
. 
1.2.3 Oxidative stress and cellular defence mechanism 
High surplus of oxidants, such as ROS, which consist of free radicals and reactive 
metabolites, can imbalance antioxidative defence mechanisms to an inappropriate degree, 
which results in oxidative stress. Inefficient elimination of oxidants leads to protein, 
membrane and RNA/DNA damaging that might cause the cell to undergo necrosis or 
apoptosis (Durackova, Z., 2010). ROS are generated during normal cellular metabolism and 
can also be involved in many signaling pathways (Jabs, T., 1999). The physiological aerobic 
process of molecular oxygen reduction occurs mainly at the mitochondrial respiratory chain 
and produce ROS such as superoxide anion (O2), hydrogen peroxide (H2O2), hydroxyl 
radical (OH•), and organic peroxides (Fridovich, I., 1978, Poyton, R. O., 2009). To avoid 
toxic accumulation, antioxidants such as phase II enzymes conjugate oxidized proteins, 
biotransform these proteins in a water-soluble compound, which can than be excreted through 
urine or bile. A major role in the cellular defence against oxidative or electrophilic stress is 
the activation of the NF-E2-related factor 2 (Nrf2)-antioxidant response element (ARE) 
signaling pathway. This pathway regulates the expression of genes coding for proteins, which 
are crucial in the detoxification and elimination of reactive oxidants and electrophilic agents 
(Nguyen, T., 2009, Lee, J.-M., 2005). It is well known that the activation of Nrf2 is controlled 
by the cytosolic protein Kelch-like ECH-associated protein 1 (Keap1). The pathway and 
mechanism by which Keap 1 acts to inhibit Nrf2 activation is still not fully characterized. 
Upon activation, cytosolic Nrf2 is translocated to the nucleus and binds to the ARE sequence 
in the promoter regions of many detoxificativ and antioxidativ proteins and initiate the 
transcription for instance of glutathione S-transferase (GST) (Sakai, M., 1988), NAD(P)H 
quinone oxidoreductase-1 (NQO1) (Favreau, L.V., 1991) or haem oxygenase 1 (HO-1). GST 
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and NQO1 are two major detoxification enzymes and are directly activate by Nrf2, whereas 
HO-1 can also be regulated by other transcriptional factors such as hypoxic inducible-factor 1 
alpha (Hif1a) (Ockaili, R., 2005, Kim, Y-M, 2011). In stroke pathology oxidative stress is 
profound, thus, Nrf2-ARE signalling pathway might be a major player to influence 
ischemia/reperfusion-provoked oxidative injury of brain tissue caused by ROS and could have 
an enormous impact in improving outcomes of ischemic brain disease. 
 
 
 
Figure 3: Overview of the ischemic cascade. ATP = Adenosintriphosphat; Na+ = Sodium-
Cation; K+ = Potassium-Cation; H+ = Hydrogen-Cation; NMDA = N-methyl D-aspartate; 
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ER = Endoplasmatic 
Reticulum; ROS = Reactive Oxygen Species; MPT = Mitochondrial Permeability Transition. 
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1.2.4 Neuroinflammation  
After brain ischemia, microglia and astrocytes become activated following subsequent 
sequestering of a subset of inflammatory mediators, ROS or proteases, which elevates the 
vulnerability of neurons, disrupt the blood-brain barrier (BBB) and stimulate formation of 
gliosis (Silver, J. 2004). Cytokines abet expression of adhesion molecules on the endothelial 
cell surface mediating the infiltration of neutrophil granulocytes, monocytes and macrophages 
(Iadecola, C., 1997). Additionally, local secretion of chemokines attracts and activates 
microglia as well as astrocyte and extravasated leukocytes (Ritter, L.S., 2000, Wang, Q., 
2007).        
Ca2+-induced activation of intracellular signalling pathways, the rise of ROS and the condition 
of hypoxia itself jointly trigger the expression of a number of pro-inflammatory genes by 
inducing the expression of several transcriptional factor such as nuclear factor-kB, hypoxia 
inducible factor 1 or interferon regulatory factor 1 (O’Neill, L.A. 1997, Ruscher, K. 1998). 
Tumour necrosis factor α (TNFα) or interleukin 1β (IL-1β) are examples of induced genes by 
injured brain cells (Hopkins, S.J., 1995). IL-6, IL-10 and IL-1β expression is massively 
upregulated after ischemic stroke. In vivo overexpression of the IL-1β receptor antagonist IL-
1ra decrease lesion volume after tMCAO indicating a crucial role for this proinflammatory 
response (Yang, G.Y., 1999, Waje-Andreassen, U., 2005). IL-1β is closely involved with 
expression of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1), E- and 
P-selectins (Lindsberg, P.J., 1990, Gong, C., 1998) after ischemia. Peak expression is evident 
between 6 and 12h after onset of stroke (Wang, X.K., Feuerstein, G.Z., 1995). Genomic 
deletion of ICAM-1 in vivo showed reduced infarct volume after tMCAO, proposing that 
activation of ICAM-1 by IL-1β plays an important role in IL-1β-induced injury (Soriano, 
S.G., 1996). Recanalisation of occluded brain vessels ameliorates brain damage but on the 
other hand leads to a secondary reperfusion injury (Hossmann, K.A., 2006, Simi, A. 2007). 
The inflammatory response is more severe due to participation of blood-borne or peripheral 
immune cells. High expression of adhesion molecules predestined invasion of non-brain 
immune cells by interaction with their complementary cell surface receptors. Neutrophils 
followed by macrophages and monocytes adhere and cross the endovascular wall to enter the 
brain paryennchyma. Chemokines such as monocyte chemoattractant protein 1, which is 
produced by damaged brain cells and is pivotal for microglia activation, becomes one of the 
main chemoattractant mediators for peripheral immune cells (Chen, Y., 2003). Macrophages 
and monocytes migrate to the lesion side and fortify immune response. They become the 
predominant immune cell type 5-7 days after stroke (Iadecola, C., 1997). Microglia activation 
                                                                 Introduction                                                                 .                   
  15 
is evident already after 30 min of ischemia. The number of activated microglia progressively 
increases with time (Rupalla, K. 1998). Microglia might act and maintain following 
inflammatory cascade by an early-response and is a focus of stroke research for 
therapeutically intervention (Polazzi, E., 2010).    
 
1.3 Progression of the ischemic insult 
The progression can be characterized by three phases after onset of stroke. Once, the cerebral 
blood flow is interrupted by occlusion or rupturing of a vessel, lack of nutrients and oxygen 
induces ischemic cascades and initiates the acute phase within minutes to hours. As a result, 
tissue ph shifts towards to a homeostatic imbalance. Chain-linking deleterious ischemic 
mechanisms occur such as glutamate release or increase of intracellular calcium, which cause 
excito- and intoxicity. Water accumulation in the interstitial space provokes cell swelling and 
tissue edema and can elevate the ICP. Cell damage is exacerbated via ROS production by 
mitochondria dysfunction, as well as misfolding of proteins by ER stress. Influx of high 
concentration of calcium triggers activation of endonucleotidases, phospholipases and 
proteinases, which induces decomposition of membrane integrity, DNA degradation or 
protein malfunction. After few hours to a few days of ischemia, the second subacute phase 
develops and is characterized by an apoptotic and neuroinflammatory response as a 
consequence of the stimulatory induction of the acute phase (Hossmann K.-A., 2006, Dirnagl, 
U., 1999, Barone, F.C., 1999). Both, glutamate excitotoxicity and calcium neurotoxicity 
subsequently spread beyond the ischemic core region formed in the acute phase to the 
surrounded area and impair normal physiological homeostatic conditions leading to apoptosis, 
inflammatory reactions and overactivation of proteolytic enzyme systems. These processes 
are accompanied by deprived cerebral blood flow and allow the demarcation of a described 
pathological area, namely the penumbra. The last phase or the chronic phase is defined by a 
complete lesion and tissue repair and regeneration (Chu, L.S., 2006) (Fig. 4).  
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Figure 4: Progression of the structural lesion accompanied by decline of functional 
areas. Progression of stroke can be subclassified into an acute, subacute and chronic phase. 
Impairment of function is mostly prominent after minutes within the acute phase but can 
persist or even increase due to structural lesion grow in the subacute phase. Early in the 
course of stroke, clinical symptoms mostly reflect an impairment of function. Some functions 
recover either spontaneously, or because of therapy (modified from Dirnagl, U., 1999). 
  
1.3.1 Concept of the peri-infarkt region, the penumbra 
The conception of penumbra rose in 1977, in which Astrup and colleagues (Astrup, J. 1977)   
demonstrated that after onset of stroke in non-human primate, brain electric activity in some 
regions are disturbed. After return of normal blood flow, these regions restored and were able 
to maintain temporary action potentials. Astrup and colleagues named the refunctional brain 
area “penumbra”, a terminology from the astronomy indicating half-light and half-shadow.  
The original definition of the ischemic penumbra describes damaged but not yet dead brain 
areas around the unsalvageable, non-reperfused and dead ischemic core. Since the last 
decades, stroke research entlightend physiological parameters and contributed to the better 
understanding of penumbrial tissue after ischemia. The latter contains mapping of cerebral 
blood flow, the quantification of oxygen and glucose rate and elucidation of the metabolic 
threshold (Baron, J.C., 2001). Based on these data, focus was shifted to the intricate cellular 
mechanism of neuronal cell death. Exitotoxicity, oxidative stress, inflammatory as well as 
apoptotic-like mediators were depicted. Thus, penumbral science covered an active field of 
molecular biology, which gathered multiple targets for neuroprotective therapeutic 
intervention, only with one goal: to rescue neurons in the tissue at-risk. It is possible in our 
days to image the penumbra region after stroke. Positron emission tomography (PET) 
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identifies brain areas suffering from reduced blood flow, although still metabolic active. 
Furthermore, magnetic resonance imaging (MRI) allows visualizing ischemic tissue that 
succumbed cell swelling and necrosis. With both mothods, we are now able to “see” the 
penumbra in real-time. The problem still remains. Why is only one common acceptable 
therapy for acute stroke existing to date? This is an interesting matter and will be challenged 
in the “Discussion” section.  
 
1.4 Animal models of cerebral ischemia 
 
Animal models of cerebral ischemia already exist for over 160 years (Fluorens, M., 1847 cited 
by Durukan, A., 2008). Cerebral ischemia in humans can differ referring to localization, 
causation, degree of insult and reversibility of injury. To guarantee the appropriate 
transmission and interpretation of data to human, several different surgery methods to model 
ischemia were developed in animals. In general one can distinguish between focal and global 
models. Global models are often applied to investigate cardiac arrest-induced cerebral 
damages. In contrast, focal models are more relevant to simulate ischemia of focal origin 
(Mhairi Macrae, I., 1992, Hunter, A.J., 1995).  
 
1.4.1 Models of global ischemia 
1.4.1.1 Extravascular methods 
Decapitation 
Decapitation leads to immediate global ischemia. The head is stored at room temperature (37 
degrees) for a defined period and can biochemically, pathophysiologically and histologically 
analysed afterwards (Ginsberg, M.D., 1989).     
 
Cardiac arrest 
Heart beat can be chemically stopped, thus ischemia is evident in the whole body. After a 
predetermined time, the animal is reanimated. This model of global ischemia in animals 
evokes similar cerebral damage as can be observed in humans with cardiac arrest (Mhairi 
Macrae, I., 1992).    
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1.4.1.2 Intravascular methods 
Model of 2-vessel occlusion 
The model of 2-vessel occlusion is induced by bilateral common carotid artery occlusion, 
which is accompanied with systemic hypotension. Hereby, cerebral blood flow is significantly 
reduced in the forebrain (<5% of control in the cortex) (Kagstrom, E. 1983b). Oscillated 
changes between both the ischemia and reperfusion are almost immediate. This model of 
forebrain ischemia was designed to study characterized cerebral energy state following 
incomplete ischemia, especially in selective vulnerable brain regions such as the 
hippocampus, caudoputamen and neocortex (Eklof, B. 1972a, Smith, M.L., 1984b).     
 
Model of 4-vessel occlusion  
The model of 4-vessel occlusion is technically more difficult to perform. In contrast to the 2-
vessel occlusion model, atraumatic claps are placed loosely around both common carotid 
arteries following electrocauterisation of the vertebral arteries, forebrain ischemia can be 
induced by occlusion of the common carotid arteries by tightening the claps, while the animal 
is awakened. Greater deviation in lesion size and mortality rate is a reason why the 2-vessel 
occlusion model is more commonly used. Pathohistological changes between these two 
models are comparable (Pulsinelli, W.A. 1988; Ginsberg, M.D. 1989, Smith M.L. 1984b). 
 
1.4.2 Models of focal ischemia 
Vessel occlusion by photochemistry 
Vessel occlusion by photochemistry is mediated by intravenous injection of photosensitizing 
dyes such as rose bengal. The location of the desired infarct is craniotomied with the Dura 
mater intact. Vessel is occluded by expose to an argon dye laser beam. Hereby, rose bengal 
becomes activated, which leads to intravasal aggregation of thrombocytes and in consequence 
in thrombotic formation. This model requires only a small craniotomy, and the Dura mater 
remains intact. The procedure exhibits consistent infarction in the frontoparietal neocortex. 
There are no thermal damages observed around the affected tissue (Watson, B.D. 1997, 
Hunter, A. J.  1995). 
 
Vessel occlusion by embolisation  
The model of vessel occlusion via embolization is based on the artificial formation of a 
thrombus within the cerebral arteries. Injection of coagulation factors such as thrombin 
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together with artificial macrospheres (300-400 µm diameters) lead to thrombus formation at 
the desired location, however there is the risk to cause undesirable multiple thrombi in other 
vessels. (Rosenblum, W.I., 1977, Orset, C., 2007). 
 
Model of intraluminal occlusion 
Developed by Tamura, A. in 1981, the occlusion of the MCA is achieved by subtemporal 
entrance with extraction of the Os Zygomaticus in rats. A less invasive modification was 
introduced by Koizumi, K in 1986 and was later modified from Longa, E.Z, 1989. This model 
became one of the most used models for focal ischemia and it is known as the intraluminal 
thread model to occlude the A. cerebri media.  This model was addopted from Hara, H.in 
1996 for mice. The intraluminal occlusion model transiently blocks the cerebral blood flow 
(CBF) in the MCA. In most cases, a silicon round-shape suture is introduced via extracranial 
arteries to the the origin of the MCA and remains for a defined period depending on species, 
age, weight etc. (Carmichael, S.T. 2005). Thread release induces recanalization and 
reperfusion of brain tissue within the blood supplying vascular territory of the MCA. This 
model mimics important apcets of human stroke realistically (Xavier, A.R., 2003). Moreover, 
the transient intraluminal thread model is predestinated to investigate the progress of ischemia 
including deprivation of nutrients and oxygen with following blood reperfusion. Thus, this 
model is closest to the human stroke pathology (Lo, E., 2008). CT and MRI determine 
ischemic degree of tissue damage between delineated penumbrial and core region in rodents 
and human congruently (Fabricius, M., 2006). Additionally, the MCAO model allows 
investigating pathophysiology of the penumbra region on the cellular and molecular level.  
  
1.5 Role of reproductive female steroid hormones in stroke 
The gonadal steroid hormones 17b-estradiol (E) and progesterone (P) have regulatory 
reproductive functions, but are also pivotal in stabilization of the bone mineral density and 
play a crucial role in prevention and protection against cardiovascular diseases (Brann, D.W., 
1995, Teede, H.J., 2007, Turner, R.T., 1994). The risk for cardiovascular events increases in 
women after cessation of the final menstrual cycle. According to that, neurodegenerative 
disorders appear in the first instance more often in postmenopausal women than in 
premenopausal women (Wyller, T.B., 1999, Appelros, P., 2009). Epidemiological studies of 
the last few decades indicated a difference between the vulnerability to stroke in same-aged 
women and men. In general more men suffer from stroke than age-matched women 
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(Merchenthaler, I, 2003, Kipp, M., 2009). Thus, gender-specific characteristics in fertile 
women were thought to play an important role in the incidence of stroke as well as in its 
outcome. In 1998, Alkayed and colleagues reported that female rats showed better outcome 
than age-matched male or ovariectomized rats after tMCAO. Conclusively, clinical pictures 
and current research results indicate that endogeneous hormonal mechanisms play a 
tremendous role in this gender-specific aspect. 
 
1.5.1 17ß-Estradiol  
Studies in the last decades focused on the regulation of hormonal events in the CNS by E, 
which is one of the three endogenous forms of estrogens. Modulation of synaptic plasticity, 
cognition, memory fine motor skills, neuroprotection and antioxidatv properties are regulatory 
mechanism of E (McEwen, B. 2002, Wise, P.M.., 2000, Roof, R.L., Hall, E.D., 2000). 
Estrogen receptors are widely expressed throughout the brain with no restriction to a specific 
cell type (Kuiper, G.G., 1997, Quadros, P.S., 2007). 
Two classical nuclear estrogen receptors (ER) were found in glia and neurons (Chaban, V.V. 
2004, Lebesgue, D., 2009, Wilson, M.E., 2009). ER-alpha (ERa) and ER-beta (ERb) are 
found around the cell nucleaur in various cell types of the brain (Ronnekleiv, O.K., 2007). 
These receptors interact with the estrogen response elements (EREs) in order to modulate 
gene expression and cell function (Klinge, C.M., 1999, Lebesgue, D., 2009). However, the 
role for both receptor isoforms in neuroprotection after tMCAO seems to be delicately 
distributed in a cell-specific manner. Experiments using cell-specific ERb knockout mice 
revealed that neuronal ERb expression is critically involved in E-mediated neuroprotection 
(Elzer, J.G., 2010). ERb has also been described to be expressed by microglia and might assist 
the attenuation of neuroinflammation by suppressing microglia activation (Mor, G., 1999, 
Saijo, K., 2011).  
ERs not only modulate gene regulation, they also mediate rapid changes in cell function. This 
fast mechanism of signal transduction by steroids is called membrane-initiated steroid 
signalling (MISS) and occurs in neurons as well as glia cells (Bondar, G., 2009). ERs are not 
restricted to the nucleus or perinuclear compartment, but are also found in the cytosol and can 
be attached to the plasma membrane (Bondar, G., 2009, Micevych, P., 2009). Specific novel 
membrane associated ERs (e.g. ER-X) which interact with different signalling cascades, in 
particular the MAPK pathway, are also discussed to facilitate neuroprotection. These ER-X 
can activate extracellular signal-regulated kinases (ERK1 and ERK2) by binding to 17β-
estradiol, while ERa may be an inhibitory regulator of the same enzymes. However, ER-X 
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seems to be structurally closely related to the classical ERa (Toran-Allerand, C.D., 2002). 
ERa can also localize to the plasma membrane where it interacts with metabotropic glutamate 
receptors (mGluRs) and, thereby, activates cell signalling pathways (Bondar, G., 2009). 
Pawlak and colleagues (2005) showed the existence of ERa, but not ERb, in plasma 
membranes of astrocytes. Treatment of astrocytes with E combined with surface biotinylation 
showed membrane trafficking of both ERa and mGluR1a in parallel which was followed by 
an increase of the intracellular calcium concentration (Bondar, G., 2009). Special membrane 
estrogen receptors, e.g. GPR30 are G-protein-coupled and thereby activate second messenger 
systems by MISS. These cell cascades imply the activation of MAPK, phospholipase C 
(PLC), protein kinase A (PKA) and protein kinase C (PKC) which in turn cause the 
phosphorylation of cAMP-responsive element binding protein (CREB) and an alteration in 
cell function (Singer, C.A., 1999, Wade, C.B., 2001, Ivanova, T., 2001; Pawlak, P., 2005, 
Ronnekleiv, O.K., 2007; Lebesgue, D., 2009). MISS not only takes place in astrocytes but has 
also been described in neurons. In isolated GABAergic and dopaminergic midbrain neurons, 
E could activate a signal transduction mechanism by binding to receptors in the membrane 
which lead to a rapid calcium release from intracellular calcium stores (Beyer, C., 1998). This 
signal transduction mechanism might be triggered by PLC. 
Altogether, estrogen is given an immensely variable role to play during neuroprotection.  
 
1.5.2 Progesterone  
Progesterone (P) has multiple functions in the CNS and regulates inflammation, neurogenesis, 
and regeneration. P often acts in concert wit E to control non-reproductive brain functions 
such as cognition and neuroprotection (Kipp, M, 2009, Acs, P.., 2009). ERs and progesterone 
receptors (PRs) are widely expressed throughout the brain with no restriction to a specific cell 
type (Kuiper, G.G., 1997; Quadros, P.S., 2007). P elicits its effect through PRs which similar 
to ERs have classically been described as nuclear transcription factors. After binding of the 
ligand to the native receptor and receptor homo-dimerization, the ligand-receptor complex 
translocates to the cell nucleus where it interacts with specific palindromic regions in the 
promoter region of different target genes. Besides that, P shows similarily to E other cell 
signaling mechanisms including interaction with membrane-associated receptors and 
stimulation of intracellular signaling cascades (Evans, R. M., 1988; Landers, J.P., 1992; Hurn, 
P.D, 2000).  
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Beside E, the sex hormone P came into focus for its neuroprotective property in the last 
decades but has not been investigated in that expanded range for pathological brain diseases 
such as E (Liu, R.L., 2010). Till now, it has been shown that P is a potent therapeutic agent 
for diverse brain injuries and diseases, including ischemic stroke (Stein, D.G., 2008; Wang, J., 
2011). P improves the neurological long-term outcome after stroke (Chen, J., 1999). It can 
dampen inflammation (Gibson, C.L., 2005; Aggarwal, R., 2008), reduce oxidative stress 
(Ozacmak, V.H., 2009), decrease edema after cerebral ischemia (Gibson, C.L., 2005; Cai, W., 
2008) and after traumatic injury (Roof, R.L., 1993) as well as activation of MAP-kinases and 
phosphoinositide-2-kinase (PI3K) (Kaur, P., 2007, Liu, R.L. 2010). A possible mechanism of 
P to facilitate neuroprotection is the inhibition of voltage-gated calcium channels which 
impedes neurotoxicity (Luoma, J.I., 2011). Furthermore, P exerts membrane stabilizing effect 
and can thereby prevent lipid peroxidation (Roof, R.L., 2000). Leukocytes have pro-
inflammatory effects in the ischemic brain and can worsen the secondary damage in the 
penumbra (Wang, Q., 2007). After ischemia, P reduces the infiltration of leukocytes in the 
brain by inhibiting the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular 
adhesion molecule-1 (VCAM-1) (Wang, J., 2011). Further studies have to show whether this 
effect of P are secondary in nature. 
 
1.6 17ß-Estradiol and progesterone action using in vivo models  
In experimental models using either males or females, the administration of E and P improved 
the outcome after cerebral ischemia as well as after traumatic brain injury (Roof, R.L., 2000). 
E application before, during or after the surgery reduced the infarct volume after transient and 
permanent MCAO (Toung, T.J.K., 1998; Rau, S.W., 2003; Suzuki, S., 2009; Zhang, Z., 
2010). E enhances post-stroke recovery and neurogenesis after tMCAO (Li, J., 2011). The 
anti-inflammatory effect of P has been validated after cerebral ischemia in mice (Gibson, 
G.L., 2005; Aggarwal, R., 2008). After permanent MCAO, P inhibits inflammatory processes 
by reducing the infiltration of leucocytes in the ischemic brain (Wang, J., 2011). P was tested 
in mice after MCAO which showed significant reduction of infarct areas as well as significant 
improvement of the survival rate, weight recovery and motor ability (Gibson, C.L., 2004). In 
the contrary to the pre-treatment paradigm with E, the pre-treatment with P did not affect the 
infarct area in mice after MCAO (Coomber, B., 2010). P seems to be most effective in co-
treatment with E (Toung, T.J.K.., 2004; Kipp, M., 2009). An up-regulation of ERa has been 
detected in the penumbra 23 hours after MCAO in rats. As there exist many promoters which 
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are able to regulate the expression of ERa mRNA (Kos, M. 2001), it is still uncertain why 
ERa is so highly expressed after MCAO and which mechanisms are responsible for that. So 
far, one can only consider a connection of the existence of ERa on astrocytes and the 
reduction of the proinflammatory function of astrocytes by activation of these receptors 
(Kipp, M. 2009). As mentioned before, neurotoxicity plays a major role in stroke. The MAP 
kinase pathway might, therefore, be involved by the trigger of neuroprotection by E. 
The neuroprotective effects of both E and P are dose-dependent (Liu et al., 2010). An 
overdose of E or P can abolish neuroprotective effects. The duration of infarct, exposure time 
of the hormones as well as age and sex of animals have also strong influence on hormonal-
mediated neuroprotection in the ischemic brain (Singh, M., 2008; Carwile, E.., 2009; Draca, 
S., 2009; Kramer, M., 2010; Strom, J.O., 2010). 
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3 Focus of thesis 
 
In the last decades, stroke research discovered many potential pharmaceutical interventions 
being able to reduce infarct volume after experimental stroke. Candidate compounds include 
calcium channel blockers, glutamate antagonists and inhibitors for leukocyte adhesion. These 
factors were subsequently clinically tested, but failed to prove effectiveness. The negative 
outcome in humane stroke trials raises the criticism about the reliability of animal stroke 
models and the translation from “bench” to “bedside”.      
There is basic evidence that 17ß-estradiol is neuroprotective after stroke in animal models. 
Furthermore, studies suggest, that progesterone might attenuate ischemic infarct volume. 
Studies were conducted so far to investigate the impact of a combined 17ß-estradiol/ 
progesterone application on histological/functional outcome after ischemic stroke in animal 
models. These studies have been performed in senescent female rats and pre-treatment with 
both hormones before tMCAO has been elaborated.  
Our first main issue was to analyse, whether 17ß-estradiol and progesterone in single or 
combinative application is neuroprotective in male rats and ovariectomized female rats in a 
survival window of 23 h after tMCAO. The effectiveness of protection was evaluated by 
measurement of the brain infarct volume which was determined by a viability dye, staining 
metabolic active brain tissue red, whereas apoptotic/necrotic tissue appears pale. Behavioural 
deficits were analyzed by means of senso-motoric testing paradigms to underline the effect of 
the steroid-induced neuroprotection on the functional level. Furthermore, to understand the 
protectiveness of steroids, we tried to unreveal involved cellular and molecular mechanisms 
within the delineated penumbra. Since anti-inflammatory properties of 17ß-estradiol and 
progesterone are already known, we aimed to analyze whether pro-inflammatory marker 
genes, as well as inflammatory cells, which are typically active in the post-stroke period, are 
diminished in the penumbra of 17ß-estradiol/progesterone treated animals. In a parallel study, 
possible endogenous defence systems against oxidative stress, which is one major event 
during cerebral ischemia were investigated. In particular, the role of Nrf2, a major regulator 
against oxidative stress, and its interaction with hormones will be enlightened in my thesis. 
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4 Materials and methods 
4.1 Materials 
Materials, chemicals and buffers/solutions, which are not noted in the “Methods” part, are 
listed here. For all buffers and solutions: if not mentioned, Aqua bidest is used as diluting agent. 
4.1.1 Materials for in vivo studies 
4-0 Ethilon     Surgical suture  Ethicon, Germany 
4-0 PremiCron   Ligation suture  B. Baun AG, Germany 
Loctite 4011 (biological tested)  Adhesive probe glue  Henkel, Germany 
Accelerator     Glue polymerisation  Bob Smith Industries, USA  
ATC 1000  Heating plate             World Precission  
      Instruments, USA 
back coupling rectal probe 
Isofluran inhalator (animals)  Vaporisor    Eickemeyer, Germany 
Fluovac    Isofluran aspirator  Harvard Apparatus, USA 
 
 
4.1.2 Materials for nucleotide analytic 
RNAse Away    RNA isolation                       Molecular Bio Prod., USA 
96-well Multiply PCR-plates  RT-rtPCR    BIOplastics, Netherlands 
optical adhesive film   RT-rtPCR   BIOplastics, Netherlands 
Easy Ladder I    RT-rtPCR   Bioline, Germany 
 
4.1.2.1 Primers 
Table 1: List of primers for gene expression analysis 
Primer Sequence bp 
Hypoxanthin-Guanine-
Phosphoribosyltransferase 
(HPRT) 
s 5’-GGTCCATTCCTATGACTGTAGATTTT-3’ 
 
 
125
 
 as 5’-CAATCAAGACGTTCTTTCCAGTT-3’  
Cyclophilin A s 5’-GGCAAATGCTGGACCAAACAC-3’ 195
 as 5’-TTAGAGTTGTCCACAGTCGGAGATG-3’  
Interleukin 6 (Il 6) s 5’-ACAGTGCATCATCGCTGTTC-3’ 160
 as 5’-CCGGAGAGGAGACTTCACAG-3’  
Cluster of Differentiation 3  
(CD 3) 
s 5’-AGAACTGCATGGAGGTGGAC-3’ 231
 as 5’-TTTCGGATGGGCTCATAGTC-3’  
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Vascular Endothelial Growth 
Factor A (VEGF-A) 
s 5’-CACATAGGAGAGATGAGCTTC-3’ 227
 as 5’-CCGCCTTGGCTTGTCACAT-3’  
Nerve Growth Factor (NGF)  s 5’-GGCATGCTGGACCCAAGCTC-3’ 460
 as 5’-GCGCTTGCTCCTGTGAGTCC-3’  
Estrogen Receptor Alpha 
(ERα) 
s 5’-CCAAAGCCTCGGGAATGG-3’ 73 
 as 5’-AGCTGCGGGCGATTGAG-3’  
Estrogen Receptor Beta (ERβ) s 5’-TGCTGGATGGAGGTGCTAATG-3’ 81 
 as 5’-CGAGGTCGGGAGCGAAA-3’  
Progesteron Receptor (PR) s 5’-AGCTCCCAGACGAAAAGACA-3’ 191
 as 5’-GAGGGCTGGTTTGGCTTT-3’  
Chemokine (C-C motif) ligand 
2 (CCL2) 
s 5’-CACATAGGAGAGATGAGCTTC-3’ 191
 as 5’-CCGCCTTGGCTTGTCACAT-3’  
Chemokine (C-C motif) ligand 
3 (CCL3) 
s 5’-CTGTTACCTGCTCAGCACCA-3’ 187
 as 5’-AAAGGCTGCTGGTCTCAAAA-3’  
Chemokine (C-C motif) ligand 
5 (CCL5) 
s 5’-TGCCCACGTGAAGGAGTATTTTTA-3’ 80 
 as 5’-TGGCGGTTCCTTCGAGTGACAA-3’  
Cluster of Differentiation 68 
(CD68) 
s 5’-TGCCCACGTGAAGGAGTATTTTTA-3’ 232
 as 5’-TGGCGGTTCCTTCGAGTGACAA-3’  
NAD(P)H: quinone 
oxidoreductase (NQO1) 
s 5’-GCCCGGATATTGTAGCTGAA-3’ 201
 as 5’-GTGGTGATGGAAAGCAAGGT-3’  
Heme oxygenase (decycling) 1  
(Hamox1) 
s 5’-CACGCATATACCCGCTACCT-3’ 226
 as 5’-AAGGCGGTCTTAGCCTCTTC-3’  
 
 
4.1.3 Materials for protein analytic 
Whatman paper    Western blot   Whatman, Brentford,  
         UK 
 
Hypercassette™      Western blot   Amersham Biosciences, 
     X-ray film development Switzerland 
chamber 
 
Tubes for homogenisation ELISA (tissue preparation) Precellys, peqlab,  
Germany      
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4.1.4 Chemicals and solutions 
 
Ammoniumpersulfat       Merck KGaA, Germany 
DNAse/RNAse free destilled H2O  Gibco, Germany 
Ethanol, pro Analysis        Merck KGaA, Germany 
Glycin                                   Roth, Germany 
Methanol            Roth, Germany 
Milk powder                       Roth, Germany 
Phosphate buffered saline (PBS)               BiochromeAG, Germany 
Sodium chloride, liquid (physiological 0.9 % NaCl)                B. Braun AG, Germany 
Sodium chloride, solid (NaCl)           Roth, Germany 
Sodiumdodecylsulfat (SDS)           Roth, Germany 
Tris(hydroxymethyl)-aminomethan (Tris)                     Roth, Germany 
Tris-HCl                    Roth, Germany 
Tris-OH                  Roth, Germany 
Triton X             AppliChem GmbH, Germany 
Tween 20              Roth, Germany 
Xylol               Roth, Germany 
 
4.1.5 Buffers and solutions  
4.1.5.1 Buffers and solutions for nucleotid analytic 
 
RNA isolation 
 
for 100 ml of 50 % (v/v) EtOH   EtOH, p.A.                     50 ml  
(washing solution)                                        DNAse/RNAse free destilled H2O                50 ml  
 
for 100 ml of 70 % (v/v) EtOH   EtOH, p.A.                     70 ml  
(washing solution)                                        DNAse/RNAse free destilled H2O                30 ml  
 
 
 
4.1.5.2 Buffers and solutions for protein analytic 
 
Western Blot 
 
4 x Stacking buffer      Tris-Base            36.94 g 
(1.5 M Tris-Base, 0.4% SDS, pH 8.8)            Aqua bidest         ad 200 ml 
       SDS      0.8 g
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4 x Running buffer     Tris-Base             18.91g 
(0.5 M Tris-Base, 0.4% SDS, pH 6.8)  Aqua bidest        ad 200 ml 
       SDS      0.8 g 
 
10 % APS      Ammuniompersulfat               0.1 g
       Aqua bidest            ad 1 ml 
 
Blotting Buffer     Tris      0.9 g  
       Glycin      4.3 g 
       Methanol    60 ml 
       Aqua bidest        ad 300 ml 
 
10 x TBST      Tris             24.22 g 
       NaCl               87.7 g 
       Tween 20    10 ml 
       Aqua bidest          1000 ml 
 
5 % Blocking Buffer     1 x TBST            100 ml 
       Milk powder        5 g 
 
 
Immunhistochemistry 
 
1 x PBS      PBS               9.55 g 
       Aqua bidest         1000 ml 
 
1 x PBST      1 x PBS          1000 ml
       Tween 20             500 µl 
 
Citrate buffer      Aqua bidest                                       1000 ml 
(pH 6.0)             Citrate acid     2.1 g 
Tween 20             500 µl 
 
        
Double-immunfluorescence  
 
10 x Tris-HCl (pH 7.6)    Tris-HCl                 61 g 
       Aqua bidest                      1000 ml 
 
 
 
 
4.2 Methods 
4.2.1 Induction of focal ischemia using the tMCAO model 
Experiments included albino Wistar rat strain, belonging to the species Rattus norvegicus, 
which were purchased from Charles River (Sulzfeld, Germany). Male rats were 12-14 weeks 
old and weighted 380-410 g, ovariectomized female rats were at the same age, but weighted   
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270-290 g. Ovariectomy was performed by the animal provider approximately 2–3 weeks 
before tMCAO. The animals underwent routine cage maintenance and were held in a 
pathogen-free and climate-controlled environment with access to water and food ad libitum.  
Animal conditions were according to the rules of ‘Care of Animal Subjects’ (North Rhine-
Westphalia, Germany). Research and animal care procedures were approved by the Review 
Board for the Care of Animal Subjects of the district government (North Rhine-Westphalia, 
Germany). This study was performed with 70 animals (58 males and 12 females). 12 animals 
died (9 males and 3 females) after tMCAO surgery. 
For surgery, narcosis of the animals was initiated by free-flow inhalation of 5% isoflurane 
(Abbott, Ludwigshafen, Germany) through a face mask for 2-3 min and maintained at 2-2.5%. 
Surplus of isoflurane was aspirated by a tube-in-tube system connected to the face mask. Core 
body temperature was stabilized during operation at 37 + 0.5 ◦C using a heating tablet and a 
lamp. By the use of Laser-Doppler flowmetry (Moor Instruments VMS-LDF2, Axminster, 
UK) cerebral blood flow was monitored on the ipsi- and contralateral side for 1 h.    
Laser-Doppler sensors were fixed 1-2 mm posterior and 4-5 mm lateral to the bregma on the 
right and on the left skull hemisphere depending on the highest blood perfusion units (BPU).   
Skull thickness was ablated on the coordinates to assure that the BPU are digitized from the 
cortical vascular territory of the middle cerebral artery and not from the external carotid artery 
(ECA) blood flow before placing the sensors. Transient MCAO was induced with minor 
changes as described previously (Herrmann, O. 2005; Kramer, M., 2010). The left common, 
the internal and the external carotid artery (CCA, ICA, and ECA) were exposed through a 
small midline skin incision in the neck region. To ensure that the BPU digitized the cortical 
vascular territory of the MCA, the common carotid artery was clipped temporary resulting in 
a decrease of BPU. The ECA was clipped transiently during the whole operation and the 
proximal CCA was ligated permanently. The vagus nerve was carefully preserved. Insertion 
of a comercially avaiable catheter (Asahi PTCA Guide Wire Soft, Abbott Vascular) was 
performed into the ICA (Fig. 5). To avoid protrusion of the A pterygopalatina, the head was 
bended aside and the catheter was introduced from the lumen of the distal CCA at the 
bifurcation to the cranial part of the ICA until an immediate drop of cerebral blood flow 
(CBF) was observed. Only those animals were included which showed a reduction of regional 
CBF by >50% compared to baseline before tMCAO.        
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4.2.2 Hormone treatment and analysis 
For hormone treatment, rats subjected to tMCAO received application of vehicle, E, P or E/P 
in a randomized manner. Hormones were dissolved initially in ethanol as a solvent and were 
further diluted in sesame oil to achieve the final concentration. Following doses were 
routinely used: E (25 µg/kg body weight) and P (10 mg/kg body weight). Vehicle treated 
animals received only sesame oil + ethanol in concentrations related to the body weight.  For 
studying dose-dependency, the following concentrations were applied: E (2.5 µg/kg and 0.25 
µg/kg body weight) and P (1 mg/kg and 0.1 mg/kg body weight). All steroid hormones were 
purchased from Sigma–Aldrich, Munich. Applications were performed subcutaneously as a 
neck depot (500 µl) direct after the end of surgery and 12 h later. The application time points 
and the concentration of hormones were determined empirically in preliminary dose-finding 
studies to yield stable plasma hormone levels corresponding to typical female estrous 
hormone levels already after 4 h of application and throughout the 23 h recovery period (data 
not shown, studies performed by Dr Kipp, Institute of Neuroanatomy, RWTH Aachen). In the 
final stage of 23 h survival period, blood samples were collected by cardiac puncture. Control 
animals (i.e. sham-operated; the catheter was not inserted in the ICA) underwent the same 
experimental protocol and receive the same vehicle volume without hormones. Individual 
steroid hormone plasma levels were analyzed by Dialog Service GmbH (Frankfurt am Main, 
Germany). Total plasma hormone titer of E and P were evaluated by using a standardized 
electrochemical luminescence technique and commercially available kits (Roche Diagnostic 
GmbH, Mannheim, Germany with detection limits of 5.0 pg/ml for E and 30 pg/ml for P). 
Figure 5: Schematic image of tMCAO 
in a rat with anatomical references. 
Insertion of the catheter into the left 
common carotid artery (red). Catheter 
maintaines in the left internal carotid artery 
and occludes the middle cerebral for 1 hr 
(modified image from Longa, E.Z., 1989). 
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4.2.3 Tissue preparation  
Twenty three hours after MCAO, all animals were killed by deep narcotization with 5% 
isoflurane and a subsequent ntraperitoneal injection with an overdose of pentobarbital (330 
mg/kg). Following transcardial perfusion with physiological sodium chloride, brains were 
dissected out of the skull rapidly and were placed into a rat brain matrix (Alto Brain Matrix 
stainless steel, 1 mm rat coronal 300–600 g; Harvard Apparatus, Holliston, MA, USA). Brains 
were subsequently cut into 2 mm coronal slices and were incubated in 2% (w/v) 2,3,5-
Triphenyl-tetrazolium chloride solution (TTC, Fluka, Germany) for 20 min at 37◦ C. TTC is a 
marker for metabolic function and represents a reliable indicator of ischemic areas for up to 3 
days after ischemia (Benedek, A., 2006; Kramer, M.., 2010; Lin, T.-N., 1993) Metabolic 
active tissue is typically stained red after TTC exposure, whereas necrotic tissue remains pale. 
Coronal slices were arranged in a frontal to occipital order, and digital photographs of all 
stained slices were taken using a Canon Digital IXUS 9015 camera (Canon, Tokyo, Japan). 
Infarct volume was estimated in a blinded manner using the freeware programm ImageJ 1.41 
(NIH, Bethesda, MD, USA). Lesion volume was calculated by summing up the infarct area of 
each slice and multiplied by 2 mm (thickness of the sections). Edema-induced volume was 
corrected using following equation (Swanson, R.A., 1990):  
 
Infarct Volume x (contralateral Volume/ipsilateral Volume). 
 
Infarct volume was calculated separately for the cerebral cortex (CX) and basal ganglia (BG).  
 
 
 
Figure 6: Schematic time line of experimental set up after 1 h tMCAO with subsequent 
hormone substitution and tissue processing at the end. BS, blood sampling; FT, functional 
testing; rCBF, regional cerebral blood flow; A1, first hormone application; A2, second 
hormone application; Final., finalization; OP, operation; occ, occlusion. 
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4.2.4 Gene expression analysis 
4.2.4.1 RNA isolation  
Isolation of RNA was performed after TTC-staining under RNAse-free conditions. Cerebral 
cortical tissue was stamped out with a biopsy puncher (pfm medical ag, Cologne, Germany) 
using a stereomicroscope (KL 200 LED, Leica, Germany) referring to the penumbra region. 
Corresponding contralateral tissue was sampled as a reference (Fig. 6). Tissue processing was 
accomplished using RNA/protein extraction kit (NucleoSpin RNA/Protein kit, Machery-
Nagel, Germany). Briefly, tissue was homogenized with 1.4 mm diameter ceramic beads 
(Precellys 24, Peqlab, Germany) at 5000 rpm for 15 s in lysis buffer delivered by the 
manufacturer. RNA was extracted with kit-provided columns. Purity was controlled using 
260:280 OD ratios (NanoDrop 1000, Peqlab, Germany).  
 
   
Figure 7: Coronal 2 mm male rat brain slices after 23 h tMCAO stained with TTC 
viability dye. (A) Ispilateral lesion side (core) remains pale after staining, whereas metabolic 
active tissue is indicated in red. Dashed line mark the punumbrial transition zone, which 
comprised cerebral cortex (CX) and basalganglia (BG). (B) For gene expression analysis, 
penumbra is punched out in the CX for the ipsilateral and contralateral side.          
 
4.2.4.2 Reverse transcription and RT-rtPCR 
Reverse transcription reactions were performed using the MMLV RT-kit and random 
hexanucleotide primers (all from Invitrogen, Germany) and standardized protocols 
(Appendix). Real-time rtPCRs (RT-rtPCRs) were carried out in a mixture consisting of 2 µl 
cDNA, 2 µl RNAse-free water (Invitrogen, Germany), 5 µl 2xSensi Mix x Plus SYBR & 
Fluorescein (Quantace, San Francisco, USA), and 0.5 µl primers (10 pmol/µl). Reactions 
were conducted in standard tubes using the MyIQ single colour real-time detection system 
(Bio-Rad, Germany) under following conditions: 10 min enzyme activation at 95 ◦C, 40 
cycles of 15 s denaturation at 95 ◦C, 30 s annealing at individual temperatures, 30 s 
 CX 
BG core 
penu- 
mbra 
contralateral ipsilateral 
 CX 
BG core 
contralateral ipsilateral 
penu- 
mbra 
punch A B
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amplification at 72 ◦C, and 5 s fluorescence measurement at 72 ◦C. External standard curves 
were generated by several fold dilutions of the target genes. The concentration of the target 
genes was calculated by comparing Ct values in each sample with Ct values of the internal 
standard curve as described previously (Acs, P. 2009; Kramer, M., 2010). Values were 
normalized using mean expression values of two housekeeping genes (hypoxanthin-guanine-
phosphoribosyltransferase) HPRT and cyclophilin A. All PCR reactions were performed in 
duplicate. Melting curve and electrophoretical analysis of the RT-rtPCR products (10 µl) plus 
ethidium bromide staining were routinely performed to specificity RT-rtPCR. For illustration, 
expression values from the ipsilateral side of vehicle-treated MCAO animals were set to 
100% and the corresponding data from hormone groups were always shown as percentage of 
this normalized value. The contralateral side of the hormone groups were included in the 
statistical analysis, but not shown in the the graphs. A list of all primers (Invitrogen, 
Germany) designed in the free-access internet program ‘‘Primer 3’’ is given in 3.1.2.1. 
 
 
4.2.5 Analysis of protein expression  
4.2.5.1 Western blotting 
For Western blotting, proteins were purified with the same extraction kit used for mRNA 
isolation (NucleoSpin RNA/Protein, Machery-Nagel, Düren, Germany). Briefly, after 
homogenization of tissue samples solubilised in lysis buffer and RNA extracted by kit-
provided RNA columns, flow-through was collected and proteins precipitated followed by the 
manufacture recommendation with one change in the protocol working flow for protein 
extraction. After precipitation proteins were washed with 95% ethanol instead of 50% to 
remove TTC staining residuals (Kramer, M, 2010). Proteins were denaturized with reducing 
agents and Protein solving buffer and subsequently incubated for 30 min with Quantification 
Reagent (all constituents of the kit). After incubation, light extinction was measured 
photometrically at 570 nm. Light extinction is caused by turbidity appearing after the addition 
of Quantification Reagent. The protein concentration is determined in reference to a Bovine 
Serum Albumin calibration curve.  
A total amount of 40µg proteins were applied and separated by SDS-PAGE using 14 % 
running gel , blotted onto nitrocellulose membranes (Hybond, Amersham) for 30 min at 10 V 
(Trans-Blot SD, Semi-Dry Transfer Cell, Bio-Rad, Germany), and incubated with primary 
antibodies diluted in 5% milk TBST over night. Unspecific binding was prevented by 
blocking with 5% milk in TBST for 30 min. Blots were incubated with primary antibodies 
                                                          Materials and methods                                                       .                         
  36 
diluted in 5% milk TBST overnight. Primary antibodies were: anti-β-actin, Sigma, USA, 
1:1000, 42 kDa; anti-CD3, Abcam, Cambridge, UK, 1:100; 16 kDa, anti-IL-6, Abcam,  
Cambridge, UK 1:100, 22 kDA . After washing and incubating with horseradish peroxidase 
(HRP) conjugated secondary antibodies (anti-rabbit-HRP, BioRad, Germany, or anti-mouse-
HRP, Abcam, both 1:5000), labelled proteins were visualized with the enhanced chemo-
luminescence (ECL) detection system (GE Healthcare, Amersham, UK). Band intensities 
were determined with Alpha-EaseFC™ software V 4.0.0 (Alpha Innotech, CA, USA) on 
autoradiography films (Eastman Kodak, Rochester, NY, USA). Quantitative analysis of 
Western blots was densitometrically accomplished with using ImageJ 1.41 (NIH, Bethesda, 
MD, USA). 
 
4.2.5.2 Enzyme-linked immunosorbent assay (ELISA)  
For ELISA  measurements, penumbrial tissue samples were homogenized by heavily shaking 
with 1.4mm diameter ceramic beads (Precellys, peqlab, Erlangen, Germany) at 5000 rpm for 
15 s using a homogenisator (Precellys® 24, peqlab, Erlangen, Germany) in 1 ml PBS (pH 7.2) 
+ several protease inhibitors (complete Mini, Roche Diagnostics GmbH, Mannheim, 
Germany). Whole lysate were taken for protein quantification (Pierce BCA Protein Assay Kit, 
Thermo SCIENTIFIC, US) and ELISA analysis. Turbidity of TTC-staining did not disturb the 
quantification procedure. Protein levels were normalized to entire protein content determined 
by BCA assay (Pierce, USA). ELISA (PeproTech GmbH, Hamburg, Germany) measurements 
were performed by quantifying the absorbance at 450 nm with corrections for 540 nm using a 
microplate reader (infinite 500M, Tecan, Germany). For quantification, standard 
concentrations of the corresponding proteins were routinely included. 
  
4.2.6 Immunhistochemistry 
Rats were narcotized as mentioned above. Before exitus letalis, thorax was opened and rats 
were first transcardially perfused with physiological sodium chloride and afterwards with 
fixative solution, which contained 2% (w/v) paraformaldehyde (Roth, Germany) with 15% 
(v/v) saturated picric acid at pH 7.4 (AppliedChem GmbH, Germany). Whole caput was post-
fixed in the same fixative solution overnight. On the following day brains were dissected out 
of the skull and were embedded in paraffin (Merck KGaA, Germany) using standardized 
protocols (Appendix). 5 µm coronal slices were cut (Jung Supercut 2065, Leica, Germany) 
and deparaffinised 10 min in Xylol. Rehydration of the slices was achieved by decreasing 
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alcohol steps from 100% for 3 min, 1 min in 95% and 70%. Finally, slices were kept in 
deionized water for 3 min, subsequently antigen retrieval was performed by boiling with 
citrate buffer for 20 min. After several washing steps for 5 min in PBST, slices were blocked  
1 h in serum (depending on source of primary antibody, blocking solution was chosen in a 
species-specific manner, Vector Laboratories, USA). Primary antibody (anti-NeuN (1:500, 
Abcam, Cambridge, UK), anti-ERa (1:250, Abcam, Cambridge, UK), and anti-ionized 
calcium-binding adaptor molecule 1 (Iba-1, 1:250, Wako, Osaka, Japan) were diluted in 
blocking serum and exposed to the slices overnight. After several washing steps with PBST, 
enzymatic activity of endogenous peroxidases was inhibited by 3% hydrogen peroxide (Roth, 
Germany) diluted in methanol for 30 min, following washing with PBST three times. Biotin-
conjugated secondary antibody (depending on primary antibody, biotinylated anti-mouse- or 
anti-rabbit was used, all 1:100, Vector Laboratories, USA) was diluted in blocking serum and 
incubated for 1 h with 5 min PBS washing step afterwards. Following incubation with a 
solution of biotin-avidin-peroxidase complexes for 1 h, antibody binding was visualized by 
substrate exposure (AEC Substrate kit, Invitrogen, Camarillo, USA).     
 
4.2.7 Double-immunfluorescence 
For double-immunfluorescence, 5 µm coronal paraffin-embedded rat brain slices were 
incubated with 0.1 % Triton X in PBS for 10 min room temperature and antigen retrieval 
using microwave, sections were blocked in Tris-HCl containing 1.5 % bovine serum albumin 
(BSA; Sigma Chemical Company, Germany) for 10 min. Slices were incubated at 4 °C 
overnight with a pair of primary antibodies diluted in TRIS containing 1.5 % BSA. The 
following primary antibodies were used for this study: rabbit polyclonal anti-Nrf2 antibody 
(abcam, ab31163, Cambridge, UK), 1:50, mouse monoclonal anti-SMI32 antibody (abcam, 
ab73273, Cambridge, UK), 1:1000, mouse monoclonal anti-GFAP antibody (abcam, ab10062 
Cambridge, UK), 1:250, and rabbit polyclonal anti-Iba1 antibody, 1:100, Wako, Japan). 
Finally, the slices were incubated with donkey anti-rabbit AlexaFluor 488 (Molecular Probes, 
USA), goat anti mouse Cy3 (Sigma, Germany) or Donkey anti-goat AlexaFluor 555 (all 
1:250; Molecular Probes, USA) for 1 h at room temperature. Nuclear staining was performed 
with bisbenzimide (Sigma, Germany). Cells were digitally photographed using a Zeiss Axio 
Z1 Imager microscope (Zeiss, Göttingen, Germany). 
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4.2.8 Morphometric quantification 
4.2.8.1 Immunhistochemistry 
Quantification of cell numbers was performed by manual counting of Iba-1-positive cells in a 
blinded manner. Cells were judged positive when the cell nucleus was clearly visible. Three 
different phenotypes of Iba-1-positiv cells according to the number of branches were 
quantified following the given criteria: Appearing round or egg-shaped, microglia was 
determined amoeboid-like. Microglia with 1-2 branches were grouped separately. Finally Iba-
1-positive-cells with more than 2 branches were also included and counted. For the 
quantification and ramification study 3 animals were subjected without hormone, whereas 2 
animals underwent hormone application. For each animal independent from treatment 6 
consecutive slices between the comissura anterior pars anterior and the comissura anterior 
were analysed. Penumbra area was determined by NeuN-staining and was carried over to the 
next corresponding slice for IBA-1 staining (Fig.7). Cell numbers were calculated and 
expressed per mm2. Cell counting was performed with a Nikon ECLIPSE 55i microscope and 
a 20 x objective.  
 
 
 
4.2.8.2 Double-immunofluorescence 
The stained slides from three tMCAO rats, three sham operated control rats and three control 
rats, without surgery, were independently scored in a double-blind fashion. The Nrf2 
immunostaining was evaluated by means of a four point scale: 0, no expression; 1, low 
expression; 2, moderate expression; 3, high expression. The semiquantitative basis for the 
A 1
2
1 
2 
core 
penu- 
mbra 
Figure 8: NeuN-stained coronal 5 µm brain slice of a vehicle-
treated male rat after 23 h tMCAO.  
(1) Staining allows delineation of the penumbra region. 
Morphological changes define the difference of vital and  
dying/dead neurons. (2) Dystrophic cells (↑) and parenchy- 
mal vacuoles (*) in the core region are presented. 
* 
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scoring was based on the apparent intensity of the labeling of specific cells and not the 
percentage of the section surface, which was positively labeled. Two observers independently 
reviewed and compared the stained slides. Using this approach inter-observer variation in 
histomorphometric scoring was minimal and the majority of scores were identical. In cases 
where variation was found, the difference was never more than one unit. 
 
4.2.9 Behavioral testing 
We assessed post-ischemic neurological deficits using motor and sensory behavioral tests 
with minor modifications as described (Garcia, J.H., 1995). Testing was performed prior 
sacrificing by two blinded readers. The following six tests were performed. Spontaneous 
activity was analyzed for 3 min within an unfamiliar environment by placing the animals in 
the middle of a 35 cm x 55 cm sized cage (scores: 3 = rat moving around, exploring the 
environment, and approaching at least three walls of the cage; 2 = slightly affected rat moving 
around in the cage but not approaching the walls and hesitating to move further, nonetheless 
eventually rising to at least one upper rim of the cage; 1 = severely affected rat not rising up at 
all and barely moving in the cage; 0 = rat not moving). For testing forepaw outstretching, rats 
were fixed at the tail, and the symmetry of the outstretching of both forelimbs was evaluated 
(scores: 3 = both forelimbs outstretched symmetrically; 2 = right side moves and outstretches 
less than left side; 1 = right side moves slightly; and 0 = right forelimb not moving). To assess 
ability to climb, rats were placed on the wall of a wire cage. Normally, rats use all four limbs 
to climb the wall (scores: 3 = rat climbing easily and gripping the wire tightly; 2 = right side 
impaired when climbing or not gripping as tightly as the left side; and 1 = rat failing to climb 
or tending to circle instead of climbing). To test body proprioception, rats were touched with a 
blunt stick on each side of the body, and the reaction to the stimulus was evaluated (scores: 3 
= rat reacts by turning head and being equally startled by the stimulus on both sides; 2 = rat 
reacts slowly to stimulus on right side; and 1 = rat not responding to stimulus placed on the 
right side). Spontaneous walking activity was staged (scores: 3 = rat walking straight ahead; 2 
= right circling; 1 = rat tending to walk toward the right side; and 0 = rat not moving). 
Sensory function was tested by brushing the vibrissae (scores: 3 = rat turns head to the 
stimulus side; 2 = rat reacts slowly to stimulus on right side; and 1 = rat did not respond to 
stimulus on right side). Individual scores of all tests were summed. An overall minimum score 
of 3 and maximum score of 18 points was achievable. 
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4.2.10 Statistics 
All data are given as arithmetic means ± SD/SEM (specified in the figure legends). If not 
otherwise stated, multiple comparisons (infarct size, brain edema, body weight, neurological 
deficit, gene expression, microglia number and morphology, protein values) were evaluated 
by one way ANOVA (analysis of variance) and further evaluated by Tukey post-hoc test or an 
independent sample t-test subsequently calculated by non-parametric Mann–Whitney U-test 
with SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA and Graph Prism). The 
criterion for statistical significance was set at P < 0.05. 
Evaluation of double-immunfluorescence Nrf2-positive cells was morphometrical staged in a 
two blinded manner. No statistics were performed.  
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5 Results 
5.1 Effect of single and combined hormone treatment after MCAO 
Laser-Doppler flowmetry was monitored for each animal to ensure reduction of rCBF in the 
vascular territory of the A. cerebri media. Occlusion resulted in abrupt decrease of rCBF more 
than 50 % of rCBF baseline levels (Fig. 9). Baseline levels were determined 5 min prior MCA 
blockage by mean of BPU for each 30 seconds. Sham-operated animals showed no change of 
rCBF (not shown). 58 male rats were included in the study and were grouped as followed: 15 
animals after tMCAO and 3 sham-operated animals received vehicle injection, 10 animals 
were subjected to E, 8 animals received P and 22 animals were treated with E and P.  
 
 
 
Figure 9: Representative Laser-Doppler measurement (tMCAO n = 13, E n = 7, P n = 6, 
E/P = 17). BPU were monitored for 60 min after occlusion of the MCA. Decrease of BPU 
was in every animal more than 50 %. Animals, which did not surpass the >50 % threshold of 
cerebral baseline blood flow are not included within this graph. E =17ß-estradiol; P = 
progesterone; BPU = blood perfusion units. 
 
 
5.1.1 Assessment of neurological deficits by functional tests 
The extent of neurological deficits was determined using behavioural evaluation scale, which 
scored sensoric and motoric qualities regarding to Garcia, J.H., 1995, with minor 
modifications. Functional testing revealed that all hormones and also the combinative 
application of both improved scoring rate (described in 3.2.9) after 23 h tMCAO (Fig. 10A). 
tMCAO-induced decrease of maximum scoring from 18 points (sham-operated without 
tMCAO or hormones) to ~7.5 points (tMCAO) was improved by the application of steroids 
with scoring rates to ~10.5 points (E), ~12.5 points (P), and ~11.9 points (E/P) in male rats. 
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The individual scoring performance for the six different tests is shown for males in Fig. 10B. 
Spontaneous activity, walking, and forepaw outstretching displayed best recovery rates, 
whereas sensory tasks showed only moderate or no recovery.  
 
 
 
Figure 10: Functional testing of male rats 23 h after tMCAO and hormone substitution 
(E = 25 µg/kg body weight/P = 10 mg/kg body weight). A total of six tests were performed 
resulting in a maximum of 18 score units in sham-operated animals (no tMCAO, no 
hormone). Panel (A) summarizes the data of all six scorings. Panel (B) shows the individual 
scores of the six tests in male animals. E, 17ß-estradiol; n, number of tested individuals per 
group; P, progesterone; *P < 0.05 tMCAO vs. sham; **P < 0.01 tMCAO vs. tMCAO plus E, 
P, or E/P. Data represent means ± SEM and are given in arbitrary units. 
 
 
5.1.2 Measurement of infarct volume by TTC viability staining  
 
Brain infarct volume without and with hormone substitution are depicted in Figure 11. Lesion 
volume in the vehicle-treated group (tMCAO without hormone application) compromises the 
ipsilateral striatal and the frontal to occipital cerebral cortical region. The tissue damage 
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precisely corresponds to the vascular territory of the MCA as indicated by the colourless 
tissue.  
 
Figure 11: Hormone supplementation reduces ischemic infarct area in the cerebral 
cortex. Serial 2 mm thick TTC-stained brain slices are arranged from frontal to occipital lobe. 
Staining reveals reduction of the cerebral cortex infarct volume in all hormone groups, 
whereas the basalganglia region (*) seems not to be protected. Ischemic core region of the 
cortex (arrowhead) is indicated by unstained brain. Arrows show penumbrial tissue. For 
infarct volume measurement brain slices are laying on squared paper. Applied hormone 
concentration: E = 25 µg/kg body weight; P = 10 mg/kg body weight.     
 
 
 
Administration of steroid hormones significantly decreased the rostral to caudal cerebral 
cortical damage. Total lesion volume was 238 mm3 for tMCAO in male rats. Lesion volume 
of E-treated group was 158 mm3, P- as well as E/P-treated group showed similar outcome 
after 23 h tMCAO indicating lesion size for P by ~ 77 mm3 and for E/P by ~ 83.3 mm3. E 
diminished cerebral cortical infarct by ~37 %, P and the co-application of both hormones 
effectively reduced infarct volume by ~ 68 % and 65 % subjected to tMCAO (Fig. 12A).  
Basal ganglia showed no reduction of infarct volume in all groups (Fig. 12B).   
+P +E/P +E tMCAO 
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5.1.3 Effect of gonadal steroids in the delineated penumbrial tissue 
Prior investigation of putative target genes of E and P, penumbrial tissue was analysed for 
tMCAO-dependent inflammation. The cytokine IL6 is known to be one of the highest stroke-
induced inflammatory markers (Yang, G.Y., 1999, Waje-Andreassen, U., 2005) (Fig.13).   
 
 
 
Figure 13: Analysis of the cytokine IL6 in the penumbra. (A) tMCAO-induced expression 
of IL6 mRNA is elevated in the ipsilateral side. Administration of E and E/P attenuates this 
increase. (B) Western blots following densitometrical quantification for ß-actin and IL6. Note 
Figure 12: Infarct volume quantification 
of cerebral cortex and basal ganglia 
after 23 h of tMCAO. (A) Infarct 
measurement of TTC-stained slices reveal 
protection by all gonadal hormones in the 
cerebral cortex. Infarct volume decreases 
after hormone supplementation of E by ~ 
37 %, ~ 65 % by P and 68 % by E/P. (B) 
No protection was measured by hormones 
in the BG. E = 17ß-estradiol, P = 
progesterone, n = numbers of tested 
animals, *P < 0.01 tMCAO vs. sham; **P 
< 0.001 tMCAO vs. tMCAO plus E, P, or 
E/P. Data represent means ± SEM and are 
given in arbitrary units.      
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that no detection (n.d.) is assessed on the contralateral side. E = 17ß-estradiol, P = 
progesterone, n = number of animals, c = contralateral, i = ipsilateral IL6 = interleukin 6, kDa 
= kd; **P < 0.01 tMCAO c, E c, P c, E/P c vs. tMCAO i, E i, P i, E/P i; #P < 0.05 tMCAO i 
vs. E/P i. Data represent means + SEM.           
  
 
The treatment with P caused no reduction, whereas E and E/P were able to diminish mRNA 
levels to the half of expression comparing to tMCAO-group, but only E/P shows significant 
effects (Fig.13A). Densitometrical quantification of Western blotting confirmed the 
dampening of IL6 expression under combined hormonal treatment (Fig. 13B). IL6 protein 
was detected only in the ipsilateral side after tMCAO and tMCAO + E/P treatment, but not in 
the contralateral side.  
Stroke-induced upregulation of CD3, a marker for T-lymphocytes, was abolished by all 
hormones. The co-application of E/P showed again a significantly decrease of mRNA 
expression referring to tMCAO (Fig. 14A). Semi-quantitative Western blot analysis supported 
this observation. Similar to the IL6 Western blot, the protein expression of CD3 was only 
detectable on the ipsilataral but not on the contralateral side after tMCAO as well as after E/P 
application (Fig. 14B). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Analysis of the T-cell specific marker protein CD3 in the penumbra. (A) High 
induction of CD3 mRNA on the ipsilateral side after tMCAO is diminished by hormonal 
exposure. (B) Densitometrical quantification of Western blots for ß-actin and CD3. Note that 
no detection (n.d.) is assessed in the contralateral side as well as after tMCAO + E/P 
treatment. E = 17ß-estradiol, P = progesterone, n = number of animals, c = contralateral, i = 
ipsilateral, CD = Cluster of differentiation, *P < 0.05 tMCAO c vs. tMCAO i; #P < 0.05 
tMCAO i vs. E/P i. Data represent means + SEM. 
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GFAP, an indicator for activation of astrocytes, is inhibited by all gonadal hormones. 
Combined hormone treatment resulted in a significant reduction of reactive astrocytes (Fig. 
15B). Infiltration, attraction or/and proliferation of microglia/macrophages, shown by CD11b 
marker, is attenuated by E/P. However, single application of hormones resulted in enhanced 
CD11b mRNA expression in the delineated penumbra (Fig. 15A).   
 
 
 
 
More detailed histomorphometrical analysis using well-defined tissue landmarks of the 
penumbra, were used to analyze the status of microglia. In tMCAO-animals treated with E/P, 
numbers of Iba1-positive cells are significantly lower (120 vs. 80 cells/mm2; Fig. 16Ai). Cell 
bodies appeared swollen, processes were enlarged and retracted, whereas E/P abolished signs 
of acute microglia activation, such as swollen somata and thickened processes as shown in the 
representative images (Fig. 16 Aiii). Quantification of morphological appearance gave more 
evidence for an amoboid shape (Fig. 16 Aii). A more specific marker for microglia, CD68, 
revealed almost no expression on the contralateral side of tMCAO animals and a 100 % 
induction on the ipsilateral lesion side. Treatment with E/P attenuated this increase resulting 
in highly significant lower ipsilateral mRNA levels compared to tMCAO alone (Fig. 16B). 
A 
B 
Figure 15: Gene expression analysis 
for CD11b, marker of microglia/ 
macrophages, and for GFAP, marker 
for activated astrocytes. 
(A) Upregulation of tMCAO-induced 
CD11b mRNA concentration on the  
ipsilateral side shows decreased values 
after combined administration of E/P.  
Single E and P application increases 
CD11b mRNA. (B) tMCAO-dependent  
elevation of GFAP on the ipsilateral 
side is strongly diminished by E/P. But 
also the single hormone treatment 
reduces activation of astrocytes. E =  
17ß-estradiol, P = progesterone, n = 
number of animals, c = contralateral, i = 
ipsilateral, CD = Cluster of  
differentiation, GFAP = glial fibrillic 
acid protein; *P < 0.05 tMCAO c vs. 
tMCAO i; #P < 0.05 tMCAO i vs. E/P i. 
Data represent means + SEM 
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Figure 16: Effect of hormone treatment on the number and morphology of Iba1-
positive microglia cells in the penumbra of male rats.  Panel (A i, ii) shows the 
quantitative evaluation of cell numbers and branching pattern in (nicht on!!!!) the 
ipsilateral side. (A iii) Representative sections demonstrating the morphological 
appearance of Iba1-positive microglial cells in the cerebral cortex penumbra on the contra- 
and ipsilateral side after tMCAO and E/P substitution. Panel (C) shows the expression and 
regulation of the activated microglia marker CD68 (ED1) mRNA in the penumbra. **P < 
0.01 tMCAO c, E/P c vs. tMCAO i, E/P i; #P < 0.05 tMCAO i vs. E/P i. Data represent 
means ± SEM with n = 3 for morphological analysis/cell quantification and n = 5–6 for 
rtPCR gene expression study. E = 17ß-estradiol; P = progesterone; n = number of tested 
individuals per group; c = contralateral; i = ipsilateral. 
 
 
Chemoattractant molecules such as chemokines play an important role for attraction and 
accumulation of microglia. The studied chemokine (C-C motif) ligand CCL2 (MCP-1), CCL3 
A 
B
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(MIP-1α) and CCL5 (Rantes) were already known to be induced by stroke. All chemokines 
were up-regulated by tMCAO. E/P inhibited the induction of CCL2 and CCL5 but further 
potentiated CCL3 expression (Fig. 17A–C). Reduced levels of CCL2 and CCL5 in the 
penumbra of hormone-treated animals were further verified on the protein level by ELISA 
(Fig. 17D-E).  
 
          
 
 
Figure 17: Expression analysis of the chemokines CCL2, CCL3 and CCL5 in male rats 
in the penumbra of the cerebral cortex after tMCAO and steroid substitution. (A, D) 
CCL2 expression; (B) CCL3 expression; (C, E) CCL5 expression; c = contralateral; i = 
ipsilateral; CCL, chemokine ligand; E = 17ß-estradiol; n = number of tested individuals per 
group; *P < 0.05 E c vs. E i; **P <  0.01 tMCAO c, E/P c vs. tMCAO i, E/P i; #P <  0.05 
tMCAO i vs. E/P i.; ##P <  0.01 tMCAO i vs. E/P i. Data represent means ± SEM. 
 
 
In addition, tMCAO enhanced the expression of ERa and ER-b but not PR within the cortical 
penumbra (Fig. 18A-C). This effect was neither abolished nor reinforced by hormone 
treatment.  
Expression of VEGF-A was up-regulated by tMCAO and further stimulated by E/P, whereas 
tMCAO-induced NGF mRNA expression was not affected by hormones. Protein anaylsis via 
E 
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ELISA resulted in potentiated expression of VEGF-A in the ipsilateral side under combined 
hormone application. 
 
 
 
Figure 18: Gene expression studies of different steroid hormone receptors in the 
penumbra and hormone treatment. (A) ERa expression; (B) ERb expression; (C) PR 
expression. c, contralateral; i = ipsilateral, E = 17ß-estradiol; P, progesterone ; ER = estrogen 
receptor; PR = progesterone receptor; n = number of tested individuals per group; **P < 0.01 
tMCAO c vs. tMCAO i; *P < 0.05 E/P i vs. E/P c; #P 6 0.01 tMCAO i vs. E/ 
P i. Data represent means ± SEM. 
 
 
 
 
A B 
C 
Figure 19: Gene expres-
sion analysis of the 
growth factor VEGF-A 
and NGF. (A, C) VEGF-A 
expression; (B) NGF 
expression; c, contralateral; 
i = ipsilateral, E = 17ß-
estradiol; P, progesterone; 
n = number of tested 
individuals per group; **P 
< 0.01 tMCAO c vs. 
tMCAO i; *P < 0.05 
tMCAO c, E/P i vs. 
tMCAO c, E/P c; #P < 0.01 
tMCAO i vs. E/P i. Data 
represent means ± SEM. 
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5.1.4 Dose-dependent effect of hormone treatment on infarct volume in male 
rats 
 
Steroid plasma levels were analyzed in male rats immediately before sacrificing. Vehicle- 
treated animals with tMCAO but without hormone supplementation showed low E and P 
values (Fig. 21). Substitution with high doses of E or P or E/P (25 µg/kg E body weight and 
10 mg/kg body weight P) yielded similar plasma hormone levels. The application of lower 
E/P doses (2.5 µg/kg, 0.25 µg/kg E body weight; 1.0 mg/kg, 0.10 mg/kg P body weight) 
resulted in much lower E/P plasma concentrations not differing significantly from untreated 
controls. Lower E/P doses revealed no or only moderate protection from MCAO in males (see 
Fig. 20).  
 
 
Figure 20: Hormone serum values of blood samples without and with hormone 
treatment in male rats. Injection of steroids occurs immediately after surgery and 12 h 
postoperative. E = 17ß-estradiol; P = progesterone; n = number of tested animals. 
 
 
 
 
 
Figure 21: Protection of the infarct 
volume with lower steroid doses. 
Measurement of the infarct volume 
measurement of animals treated with 
lower hormone concentrations 
(striped bars) are opposed to the 
hormone doses of 25 µg E/kg body 
weight and 10 mg P/kg body weight. 
E = 17ß-estradiol; P = progesterone; 
n = number of tested animals. **P < 
0.01 MCAO 
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5.1.5 Effect of combined hormone treatment on infarct volume in 
ovariectomized female rats  
 
Laser-Doppler flowmetry was monitored in ovariectomized female rats. Each animal was 
handled as described in section 4.1. Figure 22 shows a representative Laser-Doppler 
monitoring. 12 female rats were included in the study and were grouped as followed: 5 
animals were subjected for tMCAO without hormones and 4 animals received tMCAO + E/P.  
 
 
 
 
Figure 22: Representative Laser-Doppler measurement of ovariectomized female rats 
(tMCAO n = 5, E/P = 4). Occlusion of MCA results in immediate drop of BPU to more than 
50 % of baseline. E =17ß-estradiol; P = progesterone; ovx = ovariectomized; BPU = blood 
perfusion units. 
 
 
Vehicle-treated female rats yielded significantly reduced (174 mm3) infarct volumes 
compared to vehicle-treated males (258 mm3). Co-administration with high doses E/P (25 
µg/kg body E weight and 10 mg/kg body weight P) resulted in similar neuroprotective effects 
as demonstrated earlier in male rats with a decrease of infarct volume by ~55 % (Fig. 23 A-
C).  Similarily, improvement in behavioural testing in the modified Garcia scoring was 
observed in female rats treated with E/P after tMCAO compared to tMCAO only. The total 
scoring from 18 points (sham-operated without tMCAO and hormones) was significantly 
decreased by tMCAO to approximately 7.5 points and were preserved with similar recovery 
rates by the steroid application with ~11 points of scoring (Fig. 23D). Endogenous hormone 
serum levels of ovariectomized femele rats indicated higher E and P values in the vehicle-
group (tMCAO without hormones) compared to male rats but exhibited also higher hormone 
serum levels after E/P treatment (Fig. 24). Neither single hormone treatment nor dose-
dependent study was performed in ovariectomized female rats.  
ovx ♀ 
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Figure 23: Cortical infarct volume measurement and functional behavioral scoring in 
female ovariectomized rats. (A) Representative 2 mm thick and TTC-stained slices were 
arranged serially. Spread of infarcted cerebral cortex of hormone-treated animals is restricted 
to the lateral cererbral cortex (B). Basal ganglia are not protected (*) The hormone-dependent 
reduction of lesion volume of ovariectomized female is compared with the infarct volume of 
male rats with tMCAO and tMCAO + E/P (C). The functional outcome between female/male 
and treatment is shown in D, Signs indicating core of infarct (arrow-head) and penumbra 
(arrow). E = 17ß-estradiol; P = progesterone; n = number of tested animals; ovx = 
ovariectomized; (C) *P < 0.05 MCAO vs. + E/P; **P < 0.01 MCAO vs. + E/P; #P < MCAO 
male vs. MCAO female; (D) *P < 0.05 Sham vs. MCAO; **P < 0.01 MCAO vs. +E/P.   
 
 
 
 
Figure 24: Hormone serum values of male and ovariectomized female  
rats with and without hormone substitution.  
Plasma analysis are performed with blood samples collected after 23 h  
tMCAO + E/P 
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tMCAO. Application of hormones occurs immediately after surgery and 12  
h postoperative with the specified hormone doses. E = 17ß-estradiol, P = 
progesterone; n = number of tested animals       
  
 
5.1.6 Evaluation of mortility rate after tMCAO 
All animals, which survived after surgery and fulfilled the paradigm of a successful occlusion 
of the MCA (s. 3.2.1), were include in the evaluation of mortality rate after 23 h of tMCAO. 
No sham-operated animals are listed in table 2 due to no occlusion of the MCA. Numbers of 
sham-operated animals were 3 male and 3 ovariectomized female rats.    
 
 
Table 2: Overview of numbers of tested individuals per group and mortality rate  
after tMCAO. 
 
Male     Total  
Treatment tMCAO +E +P +E/P  
Animals per group (n) 16 9 7 19 51 
Mortality (n) 3 2 1 2 8 
Female      
Animals per group (n) 7 x x 5 12 
Mortality (n) 2 x x 1 3 
Total n  63 
Total mortality (n)  11 
Total mortality (%)  17.5 
 
 
 
 
5.2 Regulation of Nrf2 during tMCAO 
 
Among a battery of genes encoding detoxifying and anti-oxidative enzymes, NQO1 and 
Hamox1 are major players in anti-oxidative stress mechanism and targets of the 
transcriptional factor nuclear factor erythroid 2-related factor 2 (NRF2). Gene expression 
analysis revealed de novo tMCAO-induced up-regulation of NQO1. Application of P neither 
increases nor decreases the mRNA level of NQO1 compared to tMCAO without hormones. 
Single administration of E initiated upregulation of NQO1, but lacks statistical significance. 
Only the combined hormone treatment of E/P fortified the expression significantly, when 
subjected to tMCAO-group (Fig. 26A). The gene expression of Hamox1 was massively 
indcued and was highly significant comparing the ipsi- and the contralateral side in each 
treated-group. There was no regulation of the mRNA expression by hormones (Fig. 26B).       
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Figure 25: Gene expression study of NRF2-induced anti-oxidative enzymes NQO1 and 
Hamox1. (A) tMCAO-elevated expression of NQO1 is significantly potentiated by E/P 
treatment. (B) No regulation of Hamox1 is triggered by hormone application. E = 17ß-
estradiol; P = progesterone; c = contralateral; i = ipsilateral; *P < 0.05 tMCAO c, P c vs. 
tMCAO i, P i; **P < 0.01 E/P c vs. E/P i; ***P < 0.001 tMCAO c, E c, P c, E/P c vs. tMCAO 
i, E i, P i, E/P i; #P < 0.05 tMCAO i vs. E/P i.  
 
 
 
Furthermore, evaluation of cell type-specific expression of NRF2 in the penumbra and in the 
contralateral cerebral cortex side, as well as on the ipsilateral healthy part of the cerebral cortex 
and corresponding contralateral side was performed with markers for astrocytes, microglia and 
neurons.  To identify Nrf2 positive cell types we performed double-immunofluorescence studies 
for Nrf2 in combination with a neuronal cell marker (SMI32), an astroglial cell marker, GFAP, 
or a microglial cell marker, Iba1 which also labels peripheral macrophages. 
Brain slices from untreated control and sham operated control rats showed only sparse 
immunoreactivity for Nrf2 (data not shown). Astrocytes (Fig. 25C), microglia (Fig. 25H) as 
well as neurons (Fig. 25M) were stained distinctly positive for Nrf2 in the penumbra region. 
In addition, we observed immunopositive Nrf2 cells in the ipsilateral healthy cerebral cortex 
which were microglia (Fig. 25 E), astrocytes (Fig. 25 J), and neurons (Fig. 25M).  In the 
contralateral cortex, Nrf2 was significantly up-regulated only in neurons but not in astrocytes 
(Fig. 25B, D) or microglia (Fig. 25G, I) compared to sham operated controls (Fig.25B, D). 
Morphometric staging of these cell parameters is indicated in Figure 24A, F and K. 
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Figure 26: Immunfluorescence co-staining and staging of Nrf2-positive astrocytes.   
Panel (A) indicates scoring of NRF2-positive astroglia quantified in the penumbra of cerebral 
cortex in the ipsilateral and corresponding contralateral side, respectively (B, C). NRF2-
positive astroglia are shown in the healthy part of the ipsilateral cerebral cortex and the 
corresponding contralateral side (D, E). For labelling anti-NRF2 (green) and anti-GFAP (red) 
antibodies against astrocytes are used for detection. Nuclei are stained with DAPI (blue). 
Overview of quantified regions in the cerebral cortex are given in the upper left microimage 
of a coronal rat slice and box-marked. Representative images show higher magnification of 
co-localisation of NRF2 and astrocytes are given as boxes in the left bottom, C-E. Scale bar = 
20 µm.             
 
 
 
 
Figure 27: Immunfluorescence co-staining and staging of Nrf2-positive microglia.   
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Panel (A) indicates scoring of NRF2-positive microglia/macrophages stained in the penumbra 
of cerebral cortex on the ipsilateral and on the corresponding contralateral side (B, C). NRF2-
positive microglia/macrophages are shown in the healthy part of the ipsilateral cerebral cortex 
and the corresponding contralateral side (D, E). For labelling, anti-NRF2 (green) and anti-
IBA1 (red) antibodies against microglia/macrophages are used for detection. Nuclei are 
stained with DAPI (blue). Overview of quantified regions in the cerebral cortex are given in 
the upper left microimage of a coronal rat slice and box-marked. Representative images  show 
higher magnification of co-localisation of NRF2 and microglia/macrophages and given as 
boxes in the left bottom, C-E. Scale bar = 20 µm.             
 
 
 
 
Figure 28: Immunfluorescence co-staining and staging of Nrf2-positive neurons.  
Panel (A) indicates scoring of NRF2-positive neurons quantified in the penumbra of cerebral 
cortex on the ipsilateral and on the corresponding contralateral side (B, C). NRF2-positive 
neurons are stained in the healthy part of the ipsilateral cerebral cortex and the corresponding 
contralateral side (D, E). For labelling anti-NRF2 (green) and anti-SMI 32 (red) antibodies 
against neurons are used for detection. Nuclei are stained with DAPI (blue). Overview of 
quantified regions in the cerebral cortex are given in the upper left microimage of a coronal 
rat slice and box-marked. Scale bar = 20 µm.             
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6 Discussion 
 
6.1 Transient MCAO in rat as a model for human stroke pathology 
The transient occlusion of the A. cerebri media in rats is a reliable animal model close to the 
human stroke pathology. One major feature of this model is reperfusion of the affected brain 
areas after the reopening of the occluded MCA followed by neuroinflammatory processes, 
which closely mimics the clinical lysis therapy.  
In our system, the tested animal breathes independently and is narcotized free-flowed with 
isoflurane using a face mask. Controlling of regional cerebral blood flow is laser-monitored 
and shows a reduction of regional blood flow by more than > 50 % of baseline levels recorded 
several minutes before blocking the MCA. As demonstrated by TTC-stainig or 
immunohistochemical approaches, tMCAO for 1 h results in loss of function and destruction 
of tissue in cortical as well as sub-cortical regions. Noteworthy, tissue damage within 
subcortical areas is a consistent phenomenon and resistant to therapeutical interventions, at 
least in the applied model. Similar observations have recently been made in latest tMCAO 
studies in rats (Ryang, Y.M., 2011).   
 
6.1.1 From “bench to bedside”: choice of the right animal model and application 
strategy  
 
Despite the large number of potentialy promising medicaments tested in experimental animal 
models, a number of clinical trials have produced negative results with the same agents (del 
Zoppo, G.J., 1995, del Zoppo, G.J., 1998, Grotta, J., 1995, Adams, R.J,. 1995). Many points 
have to be regarded as crucial parameters to transfer preclinical obervations from “bench to 
bedside”. The treatments should be applied within the temporal window of efficiancy for the 
drug and is often adminstered in wrong therepeutical timing frames (The American 
Nimodipine Study Group, 1992). Most experimental studies are conducted on young, healthy 
animals under maintained laboratory conditions. However, the typical stroke patient is elderly 
with age-related risk factors for instance artherioscleroses, hypertension and heart diseases. 
Those factors should be included in experimental setting to study stroke pathology (van der 
Worp, H.B., 2010). Also, morphological and functional differences between the brain of 
humans and animals are pathophysiologically comparable to cerebral ischemia. Cerebral 
energy metabolism and, thus, blood flow in mammals is inversely related to their body 
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weight. For example, in the rat, glucose and oxygen metabolism as well as blood flow, are 
three times as high as in humans (Armstrong, E., 1983, Nieuwenhuys, R., 1998). Neuronal 
and glial densities are also quantitatively different in various mammals (Pelvig, D.P., 2008). 
Furthermore, the human brain is gyrated and larger. Therefore, greater emphasis should be 
placed on studying experimental stroke and neuroprotection in species that are 
phylogenetically closer to humans such as non-human primates. However, those studies often 
carry ethical problems. Furthermore, several tested drugs, in most cases anti-excitotoxic 
compounds, caused severe side effects in clinical trials such as psychosis, worsen functional 
outcome or even increased mortality (Wahlgren, N.G., 2004). For instance, MK-801 
(Dizocilpine), a non-competetive antagonist of NMDA receptor, has been abandond during 
clinical trials due to significant side-effects and is ironically discussed as agent to induce 
schizophrenia in animal models (Wahlgren, N.G. 2004, Eyjolfsson, E.M., 2006). Therefore, it 
is important to design drugs with better safety profiles and more-favourable pharmacokinetics 
with fewer side-effects.  
 
6.2 Effect of short-time hormone treatment on infarct size after tMCAO 
At present, only few studies have been scoping on the role of co-treatment with both gonadal 
hormones compared to individual administration, and most studies adressed the 
neuroprotective potency of E and not P in experimentally induced cerebral stroke. 
In the present study, the analysis of neuroprotective properties of gonadal hormone treatment 
right after tMCAO and 12 h after surgery in physiological high doses demonstrates decisive 
results after a short-term survival period of 23 h. These results define the concurrence 
application of both gonadal hormones as the optimal choice to prevent ischemic damage in 
the cerebral cortex but not the subcortical brain structures such as the basal ganglia. E and P 
in single administration before, during or after stroke has been proven to be effective to 
protect cerebral cortex to a certain degree from ischemic damage (Chiappetta, O., 2007, Elzer, 
J.G., 2010, Gibson, C.L., 2004, Lebesgue, D., 2009). However, the results of our studies , 
convincingly demonsrates that both hormones are neuroprotective and the combined 
application appears to be favourable over any single treatment strategy. 
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6.2.1 Reduction of the cortical infarct volume by gonadal hormones in both 
genders  
 
Irrespective of the effectiveness to protect cerebral cortex from ischemia-induced cell death 
by combined E/P administration, single hormone substitution of E and P alone decreases 
ischemic infarct volume. Remarkably, single P treatment reduces cerebral cortical lesion more 
effectively than E alone and is even similar protective as E/P in combination.  
Impairments of different neurological parameters depend on the size of infarct volume and on 
the affected brain area. Assessment of the lesion volume as well as anatomical location by 
TTC-staining and immunohistochemistry clearly reveals no protection in the basal ganglia but 
protection in the dorsal parts of the cerebral cortex. The infarct core area is mainly restricted 
to the lateral cortical regions. Steroid treatement resulted in a reduction of infarct volume 
which can mainly be attributed to the more medially located motor area. In contrast, the more 
laterally located sensory areas are less protected by hormone treatment. In line with this 
anatomical distribution of infarct areas the neurological behavioral scoring displays improved 
motor skills (Fig. 10B, Fig. 11), whereas sensory functions are less preserved (Paxinos, G., 
2004). These findings emphasize recently published reports, where P treatment alone could 
ameliorate motor function in mice up to several days after stroke which was not paralled by 
any clear reduction of the infarct volume by P (Gibson, C.L., 2004). Moreover, single E 
administration attanuates cognitive performance after stroke (Söderström, I., 2009) and 
functional outcome after a long-term period (Li, X., 2004). Recently, long-term studies (14 
days after tMCAO) reveal an equal degree of cortical infarct prevention similar to those 
observed during short-term recovery (23 hours after tMCAO) and using the same hormone 
treatment protocol indicating that cell protection is initially started during the first 23h and 
continues for at least 14 days. Behaviroral recovery is also in this long-term study (Ulbrich, C. 
2012).      
In a male versus ovariectomized female comparison, protection of cerebral cortex is similarly 
preserved in both genders. In a former publication, protection of ischemic brain injury in 
young adult female rats is shown to be abolished in reproductive senescence female rats. 
Substitution with both ovarian hormones could alleviate stroke injury  suggesting responsible 
role of protection by the steroids in stroke-induced cererbal damage (Alkayed, N.J., 2000) 
Similar observations were described using a long-lasting pretreatment hormone application 
strategy (at least 7 days) before the onset of MCAO (Toung, T.J.K., 2004). 
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6.2.2 Dose-dependent protection of cortical infarct size by gonadal hormones   
 
The applied hormone concentrations are chosen to yield steroid plasma levels corresponding 
to those known to be present in pregnant female rats. The used hormone concentrations were 
obtained in our own pre-studies (performed by Dr. Kipp). The application strategy by 
repetitive neck depot injections of the steroids necessarily needs high doses of hormones to 
yield these steroid plasma levels. Lower concentrations of hormones fail to show 
neuroprotection of the cerebral cortex after tMCAO supporting beneficial and sustained 
protective effects by high doses of hormones. Moreover, other  in vivo studies (Acs, P., 2009; 
Ivanova, T., 2003, Trotter, A., 2006) and also a pilot study in extremely premature infants 
(Trotter, A., 1999) reveal that substitution of high dosis of steroids are crucial to obtain stable 
and beneficial protective effects.  
 
 
6.3 Protective regulation by 17ß-estradiol and progesterone after tMCAO 
 
To understand the underlying cellular and molecular mechanisms wich are involved in 
steroid-mediated neuroprotection within the penumbra, expression analysis for several 
inflammatory mediators, growth factors and markers against oxidative stress was performed 
and revealed possible new candidate proteins which might orchestrate the observed 
neuroprotective effects. 
 
6.3.1 Reduction of ischemia-induced neuroinflammation by sex hormones 
 
Stroke-induced expression of CCL2, CCL5 and IL6 is suppressed by E/P treatment. The 
chemokine CC ligand-2 (CCL2) (synonym monocyte chemoattractant protein-1, MCP-1) has 
a particular role in chemo-attraction of blood-borne cells to the injury site (Schilling, M., 
2009, Conductier, G., 2010, Semple, B.D., 2010). Improved functional recovery, reduction of 
lesion volume, macrophage accumulation and astrogliosis were evident in CCL2-deficient (-/-
) mice after traumatic brain injury (Semple, B.D., 2010). Only little is known about the role of 
the chemokine (C-C motif) ligand 5 (CCL5) (synonym for “Regulated upon Activation, 
Normal T-cell Expressed, and Secreted”, RANTES) in stroke. Recent research shows a 
particular role for CCL5 in athereosclerosis and indicates angiogenetic properties. In the 
contrary, chronic infections aggravate ischemic neuronal injury, which enhanced 
microvascular dysfunction by CCL5-mediated systemic inflammatory responses (Denes, A., 
2010b, Suffee, N., 2011). Noteworthy, E inhibits the lipopolysaccaride-induced rise of CCL5 
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levels within the brain during systemic inflammation. (Brown, C.M., 2010). Although the 
expression of the chemokines CCL2 and CCL5 is attenuated by E/P, CCL3 is potentiated 
concomitantly. The exact role of CCL3 during ischemia is still unknown. CCL3 plasma levels 
are elavated in patients after acute ischemic stroke. This indicates that CCL3 might be a 
prognostic marker for post-stroke intervention (Zaremba, J., 2006). Concerning 
chemoattraction, stem cells derived from the umbilical cord blood and implanted into the 
brain parenchyma directly migrate towards ischemic regions promoting migrition by CCL3 
(Jiang, L., 2008).  
Cytokines, which are also found in the peri-lesioned area of cerebral tissue of post-traumatic 
patients caused by brain contusion, co-operate with chemokines in the infarct region (Stefini, 
R., 2008, Denes, A., 2010a, Brown, C.M. 2010). While the role of IL6 in atherosclerosis and 
as a genetic risk factor is well known, direct regulation of IL6 during acute stroke and 
regulation of IL6 by gonadal hormones are sparse. (Yamada, Y. 2008, Vikman, P., 2007). 
Interestingly, invasion, proliferation or/and differentiation of local Iba-1-positive 
microglia/macrophages and CD3 expression, which represent a marker for lymphocytes 
(Perterfalvi, A. 2009), are inhibited by combined hormone substitution in the penumbra 
region. CD11b and CD68 mRNA levels, both established markers for activated 
microglia/macrophages (Graeber, M.B., 2009), are significantly reduced in E/P-treated 
compared to vehicle-treated animals. These findings strongly support the hypothesis that 
dampening of a chemokine reponse by E/P prevents neuroinflammatory processes within the 
penumbra region. In other in vivo models of neurodegeneration such as in experimental 
allergic encephalomyelitis (EAE) or during cuprizone intoxication, both models for MS, 
microglia are implicated in this (autoimmune) pathology and respond on E and/or P treatment 
(Jansson, L., 1994, Sandyk, R., 1996, Acs, P., 2009). Beside decreased numbers of Iba-1-
positve microglia/macrophages in E/P treated animals, more detailed morphological analysis 
indicates a shift of Iba-1-positve microglia/macrophages appearance from a swollen activated 
to a more round-shape, ameboid microglia phenotyp, which is almost indistinguishable from 
activated invading macrophages (Guillemin, G.J., 2004, Tambuyzer, B.T., 2009). It is well 
accepted that steroid hormones or respective derivatives regulate inflammatory response of 
microglia in an ER-dependent manner (Mor, G., 1999, Saijo, K., 2011). It is also accepted that 
activation of microglia results in a macrophage-similar round-shape ameboid phenotyp 
(Christensen, R.H., 2006). In addition, activated microglia can secrete cytokines and 
chemokines, proteases as well as ROS and therefore fortify an inflammatory response 
(Hanisch, U.K., 2004). However, a growing body of evidence assign microglia 
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neuroprotective properties such as uptake of excessive glutamate by expression of glutamate 
receptors/transporters preventing neurons from excitotoxicity (Nakajima, K. 2008), phagocyte 
cell debris, or secreting growth- as well as neurotrophic factors (Lalancette-Hebert, M., 2007, 
Napoli, I., 2010) Finally, these data suggest the possibility that sex hormones might promote 
selectively the activation of microglia but coevally inhibit the mobilization of macrophages. It 
remains to be clarrified in future studies whether the observed effect of E/P administration on 
microglia morphology is functionally involved directly or is a secondary neuroprotective 
effect in the observed steroid-mediated reduction in infarct volumes.  
 
6.3.1.1 Suppression of ischemia-induced astrocyte activation   
 
Suppression of cell activation, proliferation or/and infiltration is not restricted to 
microglia/mocrophages and peripheral lymphocytes by E/P, but also activation of astrocytes 
is attanuated by the hormones. Since astrocytes are also capable to secrete chemokines and 
prostanoids, major biological mediators for direction of microglia/macrophages and 
peripheral leukocytes or neutrophiles to regions of cerebral damage (Babcock, A.A., 2003, 
Cross, A.K., 1999, Gao, Y. J., 2010, Johann, S., 2008, Ziebell, J.M., 2010), hormone-
mediated dampening of attraction/infiltration and proliferation of brain resident or blood-
borne immuncompetent cells seems to create prerequisite conditions for a neuroprotective 
microenviroment (Denes, A.., 2010a, Kriz, J., 2006, Wang, Q., 2007).  
 
6.3.2 Neuroprotective mechanism by 17ß-estradiol and progesterone 
 
The neuroprotective action of both hormones during ischemic cerebral insults has versatile 
targets and triggers numerous of mechanisms and this aspect has been summarized in 
excellent review article by our group and others (Arnold, S., 2009, Kajta, M., 2003, Liu, M., 
2010a, Liu, R.L., 2010b). Independent of the hormone-mediated signaling pathways, 
neuroprotection during a set of brain insults is operant by both gonadal hormones. A major 
role is the controlling of brain-intrinsic inflammation, which is mediated via invasion of 
peripheral lymphatic cells after blood–brain-barrier breakdown. After tMCAO in mice, P 
influences directly certain mediators of the  inflammatory network such as attenuating TNFa, 
IL1b and TGFb induction after MCAO likely due to nitric oxidase 3 regulation (Gibson, C.L., 
2005), antagonizing NMDA receptor Ca2+ influx and activating Src–ERK signalling 
depending on the timing of hormone application before MCAO (Cai, W., 2008), increasing 
anti-apoptotic and decreasing pro-apoptotic molecules (Yao, X.L., 2005), preventing lipid 
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oxidation (Roof, R.L., 1997), and suppressing ischemia-stimulated proliferation but 
improving survival of newborn neurons (Zhang, Z., 2010b). 
Recent studies demonstrate that E maintains the endothelial function and mitochondrial 
integrity after hypoxic condtions which can be interpreted as a stabilization of the blood-
brain-barrier (Guo, J., 2010, Liu, M., 2010a, Liu, R.L., 2010b). The latter comprises reduction 
of the Ca2+-dependent excitotoxic mechanisms, which is a tremendous post-stroke cellular 
reaction (Lebesgue, D., 2009; Liu, M., 2009; Suzuki, S., 2009), supression of NADPH 
oxidase activation (Zhang, Q.-G., 2009), and counteracting oxidative stress mechaninsm by 
preventing from surplus of free radicals through thioredoxin-regulated protection in the brain 
(Chen, T.Y., 2010).  
 
6.3.3 Presence of steroid hormone receptors indicating classical nuclear 
hormone receptor pathways  
 
Gene expression analysis reveals the presence of ERalpha and beta within the penumbra, 
suggesting classical or non-classical steroid-mediating pathways. Hormones are not capable to 
further increase the expression of receptors. Nevertheless, there is convincing evidence that E 
protects from ischemic injury by acting via classical ERs (Elzer, J.G., 2010, Dubal, D.B., 
2006, Merchenthaler, I., 2003). After focal ischemia, the expression of ERs and thereby 
responsiveness of damaged tissue for E is locally induced showing early ERalpha and late 
ERbeta modulation (Dubal, D.B., 2006). Such an ischemia autonomous tissue response may 
be seen in conjunction with known aromatase induction after MCAO in local astrocytes which 
occurs mainly one day after stroke and persists for several days (Carswell, H.V., 2005). The 
importance of astroglia for steroid-mediated neuroprotection in the stroke area is well-
accepted (Arevalo, M.A., 2009, Dhandapani, K.M., 2007). Interestingly, PR is neither 
increased by tMCAO-induction nor by hormones, which has not been described in the 
literature so far. Also, non-classical G-protein coupled steroid-mediating pathways interact 
with different intracellular cell survival and death signal cascades (Arnold, S., 2009; 
Dhandapani, K.M., 2007, Kipp, M., 2009, Lebesgue, D., 2009, Misiak, M., 2010). 
  
6.3.4 Neuroprotection by Nrf2 signaling 
 
Here, the role of the nuclear factor erythroid 2-related factor 2 (Nrf2) should be underlined as 
an important player in the oxidative stress-related stroke pathogenesis. Using double-
immunofluorescence staining with antibodies directed against Nrf2 and cell type-specific 
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markers for neurons, astroglia, and microglia the cell-specific distribution of Nrf2 in the peri-
infarct area was demonstrated. During the post-stroke episode, reoxygenation of the penumbra 
results in high degree of oxidative stress, which can cause brain tissue damage at a sublethal 
level (Carbonell, T., 2007). Hence, Nrf2 activation might be beneficial and subsequently 
contribute to cell protection and survival.  
Under normal conditions inactive Nrf2 is typically proteosomal degraded within minutes but 
stabilized during activation under damaging conditions (Tanaka, N., 2010). We were able to 
demonstrate that astrocytes, microglia and neurons are immunoflouerescence-positiv for Nrf2 
in the penumbra. Quantification revealed high expression rates for Nrf2 in the ipsilateral side 
(Fig. 26A, K, F) for all cell types studied. In particular astrocytes reveal high levels of Nrf2 
expression after 23 h of tMCAO. Recent studies show preventing effects by sulforaphane or 
1,5-diCQA (1,5-dicaffeoylquinic acid) from oxidative stress in astrocytes after 
oxygen/glucose deprivation in vitro and in vivo. These effects are coupled with the Nrf2-ARE 
signaling and are mainly contributed to the upregulated expression of gluthation or NQO1 
(Danilov, C.A., 2009, Cao, X., 2010), target genes of Nrf2. Furthermore, oxidative stress is 
followed by a destruction of nigrostriatal dopaminergic neurons and reactive gliosis in the 
damaged basal ganglia caused by methamphetamine (METH) toxicity. Nrf2-deficient (-/-) 
mice exhibit increased inflammatory responses and glial activation in the striatum after 
METH administration (Granado, N., 2011). The tMCAO-induced upregulation of NQO1 is 
significantly potentiated by E/P. The expression of Hamox1 is massively induced in the 
ipsilataral side of tMCAO but shows no further up-regulation by sex hormones. It is most 
likely that expression of Nrf2-mediates anti-oxidative phase II enzymes such as NQO1 for 
scavinging ROS. Steroid hormones might aggravate translation of these typ of enzymes to an 
early time point of post-ischemic period and accelerate following cellular recovery by 
inhibiting ROS-damaging molecular processes.    
Surprisingly, we observed significant neuronal NRF2 expression in the peri-penumbral as 
well as contralateral cortex region. Therefore, unknown intrinsic Nrf2 activators might exist. 
Our analysis show abundant expression of Nrf2 in neurons resided ipsi- and contralateral in 
the healthy regions of cerebral cortex ispi- and contralaterally. In a recent study, cortical 
primary neurons have shown to expresses high levels of Nrf2 after ethanol (ETOH) exposure, 
and this effect is mainly involved in cell survival in the ETOH-related apoptotic challenge 
(Narasimhan, M., 2011). More speculative, growth factors or cyto- and chemokines which are 
typically active during ischemia may be involved in Nrf2 regulation via MAP-kinase 
signaling without occurrence of ROS. In addition to neurochemical mediators, cross-
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hemispheral neural connections might also be a possible way to activate Nrf2 in the 
contralateral side. This possibility is suggested by MRI evidence in humans undergoing stroke 
rehabilitation, as well as by experimental studies in rats (Kim, Y.R., 2005). This effect might 
play a role to prone primarily not affected brain tissue to forthcoming oxidative stress caused 
by nearby cell degeneration.  
 
6.3.5 Growth factor expression in the delineated penumbra 
 
Growth factors (GFs) ameliorate stroke outcome by attanuating ischemic-induced cerebral 
damage through their anti-apoptotic and anti-inflammatory effects, and by inducing 
angiogenesis and/or neurogenesis (Lanfranconi, S., 2011, Costa, C., 2004, Dempsey, R.J., 
2007, Solaroglu, I., 2006). In the present study, an induction of NGF and VEGF after 23 h 
tMCAO in the penumbra was observed. The expression of VEGF is potentiated by E/P after 
tMCAO which has been already demonstrated in a previous study using lung tissue (Trotter, 
A., 2009). In the brain, VEGF is expressed ubiquitously, mostly by epithelial cells from the 
plexus choroideus but also by astrocytes and neurons (Monacci, W.T., 1993, Marti, H.H., 
1999). VEGF administration mitigates the infarct volume and improved stroke outcome 
without an increase in brain oedema (Harrigan, M.R., 2003, Kaya, D. 2005).  
 
 
6.4 Sex hormones in different models of neurological disorders  
 
The neuroprotective properties by sex hormones has been proven to be effevtive in preventing 
cerebral tissue from ischemic damage (Chiappetta, O., 2007, Elzer, J.G., 2010, Gibson, C.L., 
2004, Lebesgue, D., 2009, Ulbrich, C., 2012). Moreover, E and P reduce accumulation of ß-
amyloid plaques in an animal model of Alzheimer’s disease (AD) (Caroll, J.C., 2007, Behl, 
C., 2002). In addition, cognitive decline is attenuated after the administration of estradiol 
benzoate, a derivate of E, and progesterone before hippocampal damaging by intra-
hippocampal colchicine infusions suggesting neuroprotective actions on learning, attenuating 
neuronal loss and memory impairment (Vongher, J.M., 1999). Corresponding to recently 
published manuscripts, the synchronous application of both hormones prevent from myelin 
loss and restored functional outcome in in vivo model of multiple sclerosis (2009, Acs, P., 
2009, Kipp, M., 2009). In a MPTP (1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine) rodent 
model for Parkinson’s disease (PD), E preserved loss of dopamine neurons in the substantia 
nigra, pars compacta and neurons within the striatal compartment (Dluzen, D.E., 2001, 
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Horstink, M.W., 2003). In addition, following TBI in a stab-wound model, P suppresses the 
inflammatory response. Furthermore, P affects the sodium transport from blood to brain via 
Na-K-ATPase and, thus, reduces brain edema after lesion (Grossman, K.J. 2004).  
Neuroprotective properties of steroid hormones under different neurological paradigms 
comprises not only animal models for stroke, AD, PD and TBI but are also seen in other 
neurodegenerative challenges such as epilepsy, schizophrenia and spinal cord injury 
(Velísková, J., 2000, Gogos, A., 2012, Labombarda, F. 2003). 
 
 
6.5 Gonodal hormones as a possible therapeutical intervention directly 
after stroke 
 
Several studies of long-term hormone replacement therapy (treatment over several years) in 
women revealed an increase of risk for stroke (Lisabeth, L., 2012, Wassertheil-Smoller, S., 
2003). Nevertheless, in the present study combined hormones are injected in high doses right 
after the release of MCAO in a short-range application strategy. Although the term “hormone 
substitution” is used here, the application of hormones occurs always in a short-time setting, 
exactly two times, and not continuously for a long-range. The administration of combined 
hormones early after tMCAO shows a high potency of neuroprotection which reflects the 
possible therapeutical use in cooperation with lysis therapy or even without. Colateral-
perfusion of the penumbra region might be sufficient to obtain relevant plasma levels in the 
compromised compartment. Again, treatment could proceed right after or concomitantly to 
the lysis to gain maximum effect in a short-range way with high doses.        
 
 
6.6 Conclusion 
 
The present study demonstrates several unique and novel aspects concerning the 
neuroprotective potency of gonadal steroid hormones after tMCAO.  
First, the synchronous two-times application of steroid hormones immediately after tMCAO 
and 12 h later appears to be effective for alleviating cell damage and restorating behavioral 
functions in male and ovariectomized female young rats. Concurrently, a single application of 
P only shows a similar remarkably protective effect, although it needs to be mentioned that E 
is more protective concerning behavior dysfunction, whereas P better protects cell damage. 
Cerebral cortical tissue protection and preservation of functional recovery is accompanied 
with a significant raise of hormone plasma values to levels observed in pregnant female rats. 
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Those levels could only be achieved using high doses of E and P which have been evaluated 
in preliminary studies. 
Second, the exact delineation of the ischemic core and adjacent salvageable tissue by viability 
TTC- and immunohistochemical stainings allows pinpointing the “tissue at risk” for destinct 
isolation of tissues for further molecular and cellular analysis. As a result, anylysis of gene 
different expression patterns without and with the combined steroid hormone application 
uncovers putative targets for both steroids and identifies the regulation of local and peripheral 
inflammatory processes such as attenuating the chemokines CCL2, CCL5 and the cytokine 
IL6. Coevally, hormone stimulation diminishes markers for astrocytes (GFAP), 
microglia/macrophages (CD11b, Iba-1, CD68) and lymphoctes (CD3).  
Thus, these findings can be interpreted as a steroid-dependent phenomenon to inhibit or 
dampen several pro-inflammatory aspects and simultanously induce growth factors such as 
VEGF-A in an early timepoint after onset of ischemia. This conditons might be a prerequsite 
for early recovery and rehabilition and is operant after 14 days of tMCAO with combined 
hormone treatment indicated by an unchanged infarct volume size and improved motor 
behavior outcome. It is suggested that this short-range steroid application soon after the onset 
of ischemia at high concentrations stabilizes neuronal activity/performance until reperfusion 
is sufficient to supply neurons again. At the same time, oxidative stress-related cell damage 
by reperfusion is decreased by an enhanced expression of phase II anti-oxidativ enzymes such 
as NQO1 under hormone treatment. The expression of the transcriptional factor Nrf2 in 
astrocytes, microglia/macrophages, and especially in neurons after tMCAO might be the 
predominent signaling pathway which leads to the activation of these enzymes. 
In summary, the results of this thesis suggest that a combined, high-dose hormone treatment 
for a short period of a few days might be used as an additional therapy, besides thrombolysis. 
Further experimental studies are required to analyze the long-term efficiency of both steroids 
under ischemic coinditions before translational studies in human patients should be initiated. 
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Summary 
 
Stroke is the third leading cause of mortality in the Western civilization and the first listed for 
severe disability and intensive aftercare. It is classified by the World Health Organisation as a 
pathological acute brain disease of cerebrovascular origin that can lead to long-lasting 
neurological impairments or even death.  
Two major forms of stroke exist, namely embolism of brain arteries and rupture of a brain 
blood vessel. For embolism, hitherto, lysis of blood clots by tissue plasminogen activator is 
the only accepted therapeutic option for acute stroke. Many other compounds have been 
tested in animals and pilot human trials but finally failed to prove effectiveness in human 
stroke therapy. The gonadal hormones 17ß-estradiol (E) and progesterone (P) are known to be 
neuroprotective factors in the brain preventing neuronal death or damage under different 
injury paradigms. The present study demonstrates that both steroids in combination derogate 
brain damage, improve behavioral function, and regulate decisive cellular/molecular routes of 
neuroprotective mechanism such as neuroinflammatory responses or induction of growth 
factor expression after 1 h transient middle cerebral artery occlusion (tMCAO). 51 male and 
12 ovariectomized female rats were included in the study and subjected either to single or 
combined hormone treatment. The survival period was 24 h. Effective doses of steroid 
hormones were 25 µg/kg body weight E and 10 mg/kg body weight P. The steroid hormones 
were applied two-times, immediately after tMCAO and 12 h later. The combined application 
of both gonadal hormones diminished the cerebral cortical infarct volume to a similar extent 
in both sexes by ~70%. In this context, P was more effective as E, when applied seperately. 
Evaluation of neurological scoring revealed an equal degree of improved functional motor 
performance after hormone treatment in both genders. Expression studies in the delineated 
penumbra indicated that the combined gonadal hormone treatment dampended tMCAO-
induced pro-inflammatory mediators such as interleukin 6, and the chemokines CCL2 and 
CCL5. Equally, the numbers of infiltrated microglial cells, macrophages, and lymphocytes 
were reduced after hormone application. Beside steroid-dependent anti-inflammatory effects, 
the expression of vascular endothelial growth factor A was potentiated by steroid hormones. 
In addition, nuclear factor erythroid 2-related factor 2 (Nrf2), a anti-oxidative transcriptional 
marker, was activated in the penumbra after stroke as indicated by immunofluorescence 
staining. Nrf2 was discovered in microglia, astrocytes, and neurons within the penumbra. The 
evaluation of the putative target genes of Nrf2, NAD(P)H: quinone oxidoreductase (NQO1) 
and heme oxygenase (decycling) 1 (Hamox1), revealed a tMCAO-induced upregulation of 
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these anti-oxidative enzymes on mRNA. Gonadal hormones significantly intensified NQO1 
but not Hamox1 expression.      
These data clearly indicate the short-term neuroprotective potency of a combined treatment 
with E and P under ischemic conditions in both genders in a rat model. We assume that the 
dampening of the early local neuroinflammation and the reduction of oxidative stress are both 
crucial for this neuroprotective action. Further experimental studies are required to analyze 
the long-term efficacy of both steroids under ischemic coinditions before translational studies 
in human patients can be started. 
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Zusammenfassung 
 
Der Schlaganfall ist die dritthäufigste Todesursache in der westlichen Welt. Er wird von der 
Weltgesundheitsorganisation (WHO) als eine pathologisch akute Erkrankung des Gehirns 
zerebrovaskulären Ursprungs klassifiziert mit dauerhaften neurologischen 
Beeinträchtigungen, die zum Tode führen können. Typischerweise entsteht ein Schlaganfall 
nach Verschluss eines Blutgefäßes im ZNS bzw. beruht auf einer Ruptur eines Hirngefäßes. 
Die Lyse von Thromben mit „tissue plasminogen activator“ stellt die einzige zugelassene 
akute Therapie des thrombotischen Schlaganfalls dar. Vielvesprechende Befunde neuer 
Pharmaka in präklinischen Studien konnten ihre Wirksamkeit in klinischen Studien nicht 
belegen. Die beiden Geschlechtshormone 17ß-Östradiol (E) und Progesteron (P) sind 
bekannte neuroprotektive Faktoren im Gehirn, die neuronalen Zelltod in unterschiedlichen 
Schädigungsmodellen bis zu einem bestimmten Grad verhindern.  
Die hier vorgelegte Studie demonstriert, dass beide Steroide in Kombination den Hininfarkt in 
einem Tiermodell nach einstündigem Verschluss der Arteria cerebri media (tMCAO) 
vermindern, Verhaltensdefizite reduzieren und zelluläre bzw. molekulare neuroprotektive 
Mechanismen regulieren, z.B. neuroinflammatorische Prozesse, Expression von 
Wachstumsfaktoren, die für das Schlaganfallgeschen von großer Bedeutung sind. 51 
männliche und 12 weibliche ovariektomierte Ratten wurden in die Studie miteinbezogen. Die 
Tiere wurden entweder einer Einzel- oder Kombinationsgabe der Hormone nach tMCAO 
unterzogen. Die Überlebensdauer bis zu den Untersuchungen betrug 24 h. Die verwendeten 
Hormondosen waren 25 µg/kg Körpergewicht E und 10 mg/kg Körpergewicht P. Die Gabe 
der Steroidhormone erfolgte zweimalig, unmittelbar nach dem Eingriff und 12 h postoperativ.  
Die kombinierte Kurzzeitgabe der Hormone verminderte das kortikale Infarktvolumen in 
beiden Geschlechtern um ca. 70%. Progesteron war als Einzelkomponente deutlich wirksamer 
als Östrogen. Die Verhaltensstudien zeigten eine gleichermaßen ausgeprägte Verbesserung 
der motorischen Leistung in beiden Geschlechtern nach Hormonapplikation. Genexpres-
sionsstudien in den Penumbra belegten, dass pro-inflammatorischen Mediatoren wie das 
Zytokin Interleukin 6 und die Chemokine CCL2 und CCL5, die nach Schlaganfall verstärkt 
exprimiert werden, durch die Gabe von E und P reduziert sind. Ebenso wird die generelle 
inflammatorische Antwort nach Ischämie durch die beiden Hormone positiv beeinflusst. Die 
Anzahl an Mikrogliazellen, Makrophagen und Lymphozyten in der Penumbra ist nach 
Hormonsubstitution deutlich reduziert. Neben Steroid-abhängigen anti-inflammatorischen 
Eigenschaften, wurde die Expression des „vascular endothelial growth factor“ A durch die 
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kombinierte Gabe beider Steroide verstärkt. Die Aktivierung von anti-oxidativen 
Stressmarkern wie dem „nuclear factor erythroid 2-related factor“ 2 (Nrf2) wurde durch 
zellspezifische Doppel-Immunfärbungen in Mikrogliazellen, Astrozyten und Nervenzellen 
innerhalb der Penumbra gezeigt. Die Evaluierung von vermeintlichen Nrf2 Zielgenen wie 
NAD(P)H: „quinone oxidoreductase“ (NQO1) und „heme oxygenase (decycling)“ 1 
(Hamox1) zeigten eine Schlaganfall-verursachte Induktion dieser anti-oxidativen Enzyme. 
Gonadale Steroide verstärkten die Expression von NQO1 nicht aber von Hamox1.  
Diese Befunde zeigen, dass beide Steroidhormone als mögliche neuroprotektive Faktoren 
beim Schlagannfall in Betracht kommen. Diese positive Wirkung beruht vermutlich auf einer 
akuten Dämpfung lokaler inflammatorischer Prozesse bzw. von oxidativem Zellstress im 
geschädigten Hirnareal. Weitere Studien müssen dieses protektive Potential in 
Langzeitversuchen überprüfen, um eine translationale Übertragung der Therapiestrategie in 
humane Studien zu ermöglichen.          
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Abbreviations 
 
AD    Alzheimer disease 
ADP    adenosindiphosphat 
AMPA   α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANT    adenine nucleotide translocase 
APS    ammoniumpersulfat 
ARE    antioxidant responsive element  
ATP    adenosintriphosphat 
BBB    blood-brain-barrier 
BPU    blood perufusion units 
BW    body weight 
CAA    cerebral amyloid angiopathy 
cAMP    cyclic adenosine monophosphat 
Ca2+    calcium-cation 
CBF    cerebral blood flow 
CCL    chemokine (C-C motif) ligand 
CD    cluster of differentiation 
Cl-    chloride-anion 
CNS    central nervous system  
CSD    cortical spreading depression  
CT    computer tomography  
CVT    cerebral venous thrombosis 
DNA    desoxyribonuclein acid 
E    17ß-estradiol 
EAAT    excitatory amino acid transporter 
ECA    external carotid artery  
ECL    enhanced chemo-luminescence  
ELISA    enzyme-linked immunosorbent assay  
EPSP    excitatoric post-synaptical potential  
ER    endoplasmic reticulum  
ERa    estrogen receptor alpha 
ERb    estrogen receptor beta 
EREs    estrogen response elements 
ER-X    membrane associated estrogen receptors  
ESPro    erlangen stroke project 
etc.    et cetera 
ETOH    ethanol 
GABA    gamma-Aminobutyric acid 
GF    growth factor 
GFAP    glial fibrillic acidic protein 
GST    glutathione S-transferase 
h    hour 
H+    hydrogen cation 
Hamox 1   Heme oxygenase (decycling) 1 
HCl    hydrogen chloride 
HCO3-    hydrogen-carbonate-Anion 
Hif1a    hypoxic inducible-factor 1 alpha      
HO-1    heme oxygenase 1 
HPRT    hypoxanthin-Guanine-Phosphoribosyltransferase 
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Iba1    ionized calcium-binding adaptor molecule 1 
ICAM-1   intercellular adhesion molecule 1  
ICP    intracranial pressure 
IL    interleukin 
K+    potassium-cation 
kg    kilogram 
NQO1    nAD(P)H quinone oxidoreductase-1  
OH    hydroxy group 
P    progesterone 
pH    potentia hydrogenii 
PI3K    phosphoinositide-2-kinase  
PKA    protein kinase A  
PKC    protein kinase C 
PLC    phospholipase C  
PD    Parkinson disease 
PR    progesteron receptor 
qRT-PCR   quantitative- Real-Time-PCR 
rCBF    regional cerebral blood flow  
RIND    reversible ischemic neurological deficit 
RNA    ribonuclein acid 
ROS    reactive oxygen species 
mGluRs    metabotropic glutamate receptors  
M    molar 
MAP-kinase   mitogen-activated protein kinase  
MCA    middle cerebral artery 
MCAO   middle cerebral artery occlusion 
MCP-1   monocyte chemotactic protein-1 
METH    methamphetamine 
mg    milligram 
ml    millilitres 
min    minutes 
MIP-1α   macrophage inflammatory protein 1α 
MISS    membrane-initiated steroid signalling  
MPTP     1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine 
MPT =    mitochondrial permeability transition 
MRI    magnetic resonance imaging  
MS    multiple sclerosis 
mV    millivolt 
Na+    sodium-cation 
NaCl    sodium chloride 
NF-κB    nuclear factor- κB 
NGF    nerve growth factor 
nm    nanometer 
NMDA   n-methyl d-aspartate 
NQ1    NAD(P)H: quinone oxidoreductase 
Nrf2    nuclear factor erythroid 2-related factor 2 
P    progesterone 
p.A.    pro analysis 
PET    positron emission tomography 
PBS    phosphate buffered salt solution 
rt-PA    recombinant tissue plasminogen activator 
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s    second 
s.c.    subcutan 
SAH    subarachnoid hemorrhage 
TBI    traumatic brain injury 
TBS    tris-buffer saline 
TBST    tris-buffer saline + Tween 20 
TIA    transient ischemic attack 
tMCAO   transient middle cerebral artery occlusion 
t-PA    tissue plasminogen activator 
Tris    tris(hydroxymethyl)-aminomethan 
TTC     2,3,5-triphenyl-tetrazolium chloride  
UK    United Kingdom 
USA    United States of America 
VDAC    voltage-dependent anion channel  
VEGF    vascular endothelial growth factor 
WHO    world health organisation 
1,5-diCQA    1,5-Dicaffeoylquinic acid 
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Appendix 
 
Embedding of tissue in paraffin 
 
1. For embedding procedure, tissue should be placed in appropriate boxes after fixation 
following hydration step over night with tap water.   
 
2. For dehydrating of the tissue, following steps are suggested:  
(Cave: methylated absolute alcohol should be used; numbers (1, 2, and 3) after Aceton and 
Parafin indicate new/fresh Aceton/Parafin) 
 
70% EtOH 
3-4 days or longer,
daily change of alcohol
    
96% EtOH 0:45 min 
   
96% EtOH 0:45 min 
   
96% EtOH 1:00 min 
   
abs. EtOH 0:45 min 
   
abs. EtOH 0:45 min 
   
abs. EtOH 1:00 h 
   
Aceton 1 1:00 h 
   
Aceton 2 1:00 h 
   
Aceton 3 1:00 h 
   
Parafin 1 1-2 h 
   
Parafin 2 1 day 
   
Parafin 3 Over night or longer 
  
 
 
3. Tissue should be replaced in special metal parfin-embedding forms (bottom is wiped with 
Glycerin (Roth, Germany) to separate easily the parafin-tissue block from the metal form 
later) and should be totally covered with paraffin by an embedding machine (Histo Embedder, 
Leica, Germany). Afterwards the forms must cool down for hours or max. 1 day at room 
temperature or at 4 degrees in the freezer.    
